Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Inhibition of the Heat Shock Response by PI103 Enhances the Cytotoxicity of Arsenic Trioxide

Inhibition of the Heat Shock Response by PI103 Enhances the Cytotoxicity of Arsenic Trioxide Abstract Heat shock factor 1 (HSF1) is a key regulator of the cytoprotective and anti-apoptotic heat shock response and can be activated by arsenite. Inhibition of HSF1 activation may therefore enhance the cytotoxicity of arsenic trioxide (ATO). We show that ATO induced HSF1 phosphorylation at serine 326 (S326) and induced HSF1-dependent expression of heat shock proteins (HSPs) 27 and 70 in cultured cells. HSF1 significantly reduced cell sensitivity to ATO by reducing apoptosis. Disruption of HSF1 function not only reduced ATO induction of HSP27 and 70 but also enhanced ATO cytotoxicity by elevating apoptosis. These results reveal that HSF1 activation and the resulting induction of HSPs may protect cells from ATO cytotoxicity. The diminished expression of HSPs and hypersensitivity to ATO in cells stably depleted of HSF1 was rescued by ectopic expression of wild-type HSF1 but not an S326A substitution mutant, indicating that phosphorylation at S326 was critical for the protective effect of HSF1. Simultaneous treatment of cells with ATO and PI103, an inhibitor of members of the phosphatidylinositol 3-kinase (PI3K) family, suppressed not only ATO-induced expression of an HSP70 promoter-reporter construct and endogenous HSP70 but also phosphorylation of HSF1 S326. PI103 considerably reduced HSF1 transactivation in ATO-treated cells but had only a limited effect on HSF1 nuclear translocation and DNA binding. Furthermore, PI103 enhanced ATO cytotoxicity in an HSF1-dependent manner. Thus, inhibition of S326 phosphorylation by PI103 blocks the transactivation of HSF1 and may consequently suppress ATO induction of the heat shock response and sensitize cells to ATO. arsenic trioxide, cytotoxicity, heat shock factor 1, heat shock response, apoptosis Arsenic trioxide (ATO) is used to treat acute promyelocytic leukemia by inducing apoptosis and partial differentiation (Miller et al., 2002; Soignet et al., 1998). However, the use of ATO as a single agent in clinical trials against solid tumors refractory to current therapies was found to be ineffective or highly toxic (Dilda and Hogg, 2007; Murgo, 2001; Vuky et al., 2002). In addition, chronic exposure to inorganic arsenic is carcinogenic (International Agency for Research on Cancer, 2004; Straif et al., 2009). ATO can prolong the QT interval and lead to torsade de pointes (Barbey et al., 2003), and the U.S. FDA-approved formulation of ATO induces acute promyelocytic leukemia differentiation syndrome, neuropathy, hepatotoxicity, and hematologic toxicity in patients with a variety of hematologic and solid malignancies (Douer and Tallman, 2005). Hence, mechanistic studies that can better elucidate the mechanism of action of ATO are necessary to reduce its toxicity and/or improve clinical outcomes. Heat shock factor 1 (HSF1) is the master transcriptional regulator of the cellular response to heat and a wide variety of other stresses (Anckar and Sistonen, 2011). In response to stress, the inactive monomer HSF1 trimerizes and binds to heat shock elements (HSEs) of target genes, including those encoding heat shock protein (HSP) 27, HSP70, and HSP90, thereby driving their expression (Anckar and Sistonen, 2011; Holmberg et al., 2002). The resulting rapid and robust induction of the heat shock response (HSR) leads to a universal adaptation and protection mechanism against adverse environmental stresses and many pathophysiological conditions (Richter et al., 2010). Either the level of HSF1 or its nuclear localization can be elevated in cancer cell lines and tumor tissues (Fang et al., 2011; Santagata et al., 2011). Several reports have demonstrated that loss of HSF1 function prevents oncogenesis (Dai et al., 2007; Meng et al., 2010; Min et al., 2007) or causes a dramatic increase in sensitivity of cancer cells to hyperthermia or chemotherapy, leading to massive apoptosis (Phillips et al., 2007; Rossi et al., 2006; Wang et al., 2002; Westerheide et al., 2006). Thus, inhibiting HSF1 activation may sensitize cancer cells to death and augment chemotherapy-induced apoptosis (Whitesell and Lindquist, 2009). Moreover, a prominent feature of HSF1 is that its conversion into a transcriptionally active trimer occurs concurrently with hyperphosphorylation of serine (S) residues. Following heat stress, phosphorylation at S230 or S326 promotes HSF1 transactivation (Guettouche et al., 2005; Holmberg et al., 2001), whereas phosphorylation at S320 or S419 mediates its nuclear translocation (Kim et al., 2005; Murshid et al., 2010). In addition, S326 has been demonstrated to be the most critical serine residue for HSF1 transactivation after heat stress (Guettouche et al., 2005). The kinases responsible for phosphorylation of HSF1 have not been definitively identified. Nonetheless, inhibition of HSF1 phosphorylation may prevent its complete activation, slow cancer progression, and/or enhance therapeutic efficacy. Arsenic compounds are known to induce the expression of HSPs (Del Razo et al., 2001). The induction of HSR is a sensitive indicator of arsenic exposure and may be involved in the tumorigenicity of arsenic (Khalil et al., 2006). Suppression of arsenite-induced expression of HSP27 and HSP70 may account for the function of p27, a member of a family of cyclin-dependent kinase inhibitors and a putative tumor suppressor that induces cell cycle arrest (Liu et al., 2010). In addition, inhibition of HSP70 or HSP90 effectively enhances ATO cytotoxicity (Pelicano et al., 2006; Taylor et al., 2008; Wetzler et al., 2007; Wu et al., 2009). Given that induction of HSPs depends primarily on HSF1, it is critical to have a firm understanding of how HSF1 is activated by ATO and whether inhibition of HSF1 increases ATO cytotoxicity. MATERIALS AND METHODS Cell culture and reagents. HeLa and HEK 293T cells were obtained from the American Type Culture Collection (Manassas, VA). CGL2 cells (a HeLa cell/normal human fibroblast hybrid; Stanbridge et al., 1981) were kindly provided by Dr. E. J. Stanbridge (University of California, Irvine). Cells were routinely maintained in Dulbecco's Modified Eagle's Medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen), 0.37% sodium bicarbonate, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C in a humidified atmosphere containing 10% CO2 and were passaged twice per week. ATO (Sigma-Aldrich, St Louis, MO) was freshly dissolved in 0.1 N NaOH to make a 10mM stock solution before use. PI103, LY294002, NU7026, rapamycin, Go6976, SB203580, SP600125, and U0126 were obtained from Calbiochem (Merck KGaA, Darmstadt, Germany), dissolved in dimethyl sulfoxide to make 10mM stock solutions, and stored in aliquots at −20°C. Establishment of stable HSF1-deficient CGL2 cells. Stable depletion of HSF1 was achieved by transduction of CGL2 cells with VSV-G-pseudotyped lentivirus-based short hairpin RNA (shRNA). Viral supernatants–containing empty vector (pLKO) or HSF1-specific shRNA (TRCN7480) were obtained from the National RNAi Core Facility Platform (Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taipei, Taiwan). CGL2 cells were transduced with pLKO- or shRNA-containing supernatant (multiplicity of infection = 3) in growth medium supplemented with 10 μg/ml polybrene. At 24 h post-transduction, 2 μg/ml puromycin was added to culture medium to select for stable clones (CGL2-pLKO and CGL2-shHSF1). Depletion efficiency was examined by immunoblotting. Expression vectors and reporter constructs. To generate a retroviral plasmid–encoding wild-type HSF1 (wtHSF1, residues 1–529), full-length HSF1 complementary DNA (cDNA) was amplified by PCR using primers in which restriction sites for EcoRI and XhoI had been created (5′-GGAATTCGCCACCATGGATCTGCCCGTGGGCCC-3′ and 5′-CCGCTCGAGCTAGGAGACAGTGGGGTCCTTGGC-3′; GenBank accession number NM_005526). Products were digested with EcoRI and XhoI and then subcloned into the corresponding sites of the retroviral pFB-Neo vector (Stratagene/Agilent Technologies, La Jolla, CA). HSF1 constructs with different deletions or the S326A substitution mutation were created using the QuickChange Site-Directed Mutagenesis Kit (Stratagene) following the manufacturer's instructions. Constitutively active HSF1 (caHSF1) was obtained by deleting amino acid residues 202–316 (Zuo et al., 1995), and dominant negative HSF1 (dnHSF1) was obtained by truncating after residue 361 as described (Green et al., 1995). A GAL4-HSF1 fusion construct was obtained by inserting human HSF1 (residues 124–503) into the Gal4 DNA-binding domain–containing pFA-CMV vector (Stratagene) as described (Shi et al., 1995). To construct a human HSP70 promoter-luciferase reporter pGL4-A1A-1.3K, a fragment from −1310 to +155 bp relative to the transcription start site of HSP70 (HSPA1A) was cloned by PCR amplification from a BAC clone (RP11-1104F14; Invitrogen) using primers 5′-ACACGGTGAAACCTCGTCTC-3′ and 5′-TGAGATTGGGGGCTGGAAAC-3′. PCR products were cloned into the pJET1.2/blunt vector (Fermentas, Glen Burnie, MD) and then subcloned into the pGL4.15[luc2P/Hygro] vector (Promega, Madison, WI) with the aid of BglII and BamHI digestion. Two putative HSF1-binding elements (HSE1 and HSE2, both within ∼1.3 kb upstream of the HSP70 transcription start site) were mutated as described (Mosser et al., 1988) using site-directed mutagenesis (HSE1: −109CTGGAATATTCCCG−96 to −109CTTCAATATTGTCC−96; HSE2: −192CTGGAGAGTTCTGA−179 to −192CTTCAGAGTTGTGC−179). All constructs were confirmed by DNA sequencing. Retroviral gene delivery and establishment of stable cell lines. To generate virus particles containing each HSF1 expression construct, HEK 293T cells were cotransfected with pVPack-GP, pVPack-VSV-G (Stratagene), and either pFB-Neo (empty vector) or one of the pFB-HSF1 constructs (pFB-wtHSF1, pFB-caHSF1, pFB-dnHSF1, or pFB-S326A) using Lipofectamine 2000 (Invitrogen). At 48 h post-transfection, supernatant containing retrovirus with the specific HSF1 construct was collected, filtered through a 0.2-μm filter, and used without further purification. CGL2 and CGL2-shHSF1 cells were transduced with retrovirus-containing supernatants in growth medium supplemented with 10 μg/ml diethylaminoethyl-dextran (Sigma). At 24 h post-transduction, 1 mg/ml neomycin (Invitrogen) was added to the culture medium to select for stable cell lines (CGL2-pFB-Neo, CGL2-wtHSF1, CGL2-caHSF1, CGL2-dnHSF1, CGL2-shHSF1-pFB-Neo, CGL2-shHSF1-wtHSF1, or CGL2-shHSF1-S326A). The expression level of each construct was examined by immunoblotting. Cytotoxicity assay. Cells were seeded in at 2 × 104 cells per well in a 24-well plate, cultured for 24 h, and then treated with drugs for 24–72 h. Cytotoxicity was assayed by determining viable cell numbers using methylthiazole tetrazolium (WST-8; Cell Count Kit 8; Dojindo Molecular Technologies, Inc., Gaithersburg, MD) as described (Kakadiya et al., 2011). Analysis of apoptosis. Apoptosis was quantified by measuring the activity of caspase-9 using the CaspaTag Caspase 9 In Situ Assay kit (Chemicon). Briefly, untreated or ATO-treated cells were incubated with a carboxyfluorescein-labeled fluoromethyl ketone peptide, which is membrane permeable and binds covalently to a reactive cysteine residue of active caspase-9. The bound fluorescent reagent within cells was then measured using a flow cytometer (FACSCanto II; BD Biosciences, San Jose, CA). The caspase-9 activity was expressed as the mean fluorescence of 10,000 cells. Apoptosis was also quantified by measuring the level of cleaved poly(ADP-ribose) polymerase (PARP) in individual cells as described (Wu et al., 2010). Luciferase reporter assay. HEK 293T cells, known to display high transfection efficiencies, were transiently cotransfected with a wild-type or HSE-mutated pGL4-A1A-1.3K reporter plasmid along with a control Renilla luciferase reporter (pGL4.7; Promega) using Lipofectamine 2000. At 5 h post-transfection, cells were replated at 3 × 104 cells per well in 24-well plates and incubated for another 24 h. Cells were treated with ATO for 6 h, and luciferase activity was measured using the Dual-Glo assay system (Promega). The pGL4-A1A-1.3K stable cell line was generated by transfecting HeLa cells, which also manifest high transfection efficiencies, with pGL4-A1A-1.3K using Lipofectamine 2000. Colonies resistant to hygromycin (0.2 mg/ml) were tested for induction of luciferase expression 6 h after ATO treatment, and the colony with the highest luciferase level was selected for further studies. Cells were plated at 3 × 104 cells per well in 24-well plates 24 h prior to drug treatment. Luciferase assays were performed using the Bright-Glo assay system. To measure the transactivation activity of HSF1, HEK 293T cells were transiently cotransfected with plasmids encoding the GAL4-HSF1 fusion protein and GAL4-luciferase reporter (pFR-Luc; Stratagene) along with a control Renilla luciferase reporter (pGL4.7; Promega) using Lipofectamine 2000. After ATO treatment, luciferase assays were performed using the Dual-Glo assay system. Reverse transcription PCR. Cellular RNA was extracted with Trizol reagent (Invitrogen), and 5 μg was reverse transcribed with Superscript III (Invitrogen) and oligo-dT (Promega). A linear range of input cDNA was determined empirically via a twofold dilution series in 26- to 28-cycle reactions in the presence of DreamTaq DNA polymerase (Fermentas). PCR products were run on 1% Tris/borate/EDTA agarose gels (Sambrook et al., 1989), stained with SYBR Gold (Invitrogen), and quantified using GeneTools (Syngene, Cambridge, UK). β-actin was used as an internal control. The primer sets were 5′-CTACAAGGGGGAGACCAAGG-3′ and 5′-TTCACCAGCCTGTTGTCAAA-3′ (for HSP70) and 5′-GCACTCTTCCAGCCTTCC-3′ and 5′-GCGCTCAGGAGGAGCAAT-3′ (for β-actin). Preparation of cell lysates. Total cell lysates were prepared by boiling cells directly in Laemmli sample buffer (Laemmli, 1970). For fractionation of cytosol and nuclei, cells on plates were washed with ice-cold PBS, lysed for 10 min at 4°C in a 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (10mM HEPES, pH 7.9, 10mM KCl, 0.1mM EDTA, 0.4% [vol/vol] NP-40, 1mM phenylmethylsulfonyl fluoride, 2mM leupeptin, 2mM aprotinin, 2mM pepstatin, 25mM sodium fluoride, and 1mM sodium orthovanadate), and then scraped off the plates. The cytosolic fraction was obtained by centrifuging the cell lysate at 15,000 × g for 10 min and collecting the clear supernatant. The nuclear pellet was resuspended and further extracted for 2 h at 4°C in another HEPES buffer (20mM HEPES, pH 7.9, 0.4M NaCl, 1mM EDTA, 10% glycerol, 1mM phenylmethylsulfonyl fluoride, 2mM leupeptin, 2mM aprotinin, 2mM pepstatin, 25mM sodium fluoride, and 1mM sodium orthovanadate). The nuclear fraction was obtained by centrifuging at 15,000 × g for 10 min and collecting the supernatant. The cytosolic and nuclear fractions were subjected to immunoblot analysis and electrophoretic mobility shift assay (EMSA). Immunoblot analysis. Cell lysates were resolved by 8 or 12% SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes. Specific proteins were detected as described (Yih et al., 2005) using antibodies against HSF1, HSF1 phosphorylated at S230, HSP27, HSP70, and PARP (Santa Cruz Biotechnology, Santa Cruz, CA), HSF1 phosphorylated at S320 or S326 (Epitomics, Burlingame, CA), and FLAG and α-tubulin (Sigma). β-actin was detected with anti-β-actin (Chemicon, Temecula, CA) and was used as a loading control. Relative levels of HSF1 phosphorylation were quantified using GeneTools (Syngene) and determined by normalizing with the intensities of β-actin. Electrophoretic mobility shift assay. HSF1 binding to a consensus HSE from the human HSP70 promoter (HSE1) was analyzed by EMSA. Briefly, 2 μg nuclear extract was mixed with 20-pmol IRDye-labeled HSE1 oligonucleotide and 0.5 μg poly(dI-dC) (Sigma) in Tris buffer (10mM Tris, pH 7.8, 50mM NaCl, 1mM EDTA, 0.5mM dithiothreitol, and 5% glycerol) in a final volume of 25 μl. After a 20-min binding reaction at 25°C, an Orange Loading Dye (LI-COR, Lincoln, NE) was added, and the reaction products were loaded directly onto a 4% native polyacrylamide gel (50mM Tris, pH 7.5, 0.38M glycine, and 2mM EDTA). Gels were run at room temperature for 30 min at 80 V and then scanned under the Odyssey Infrared Imaging System (LI-COR). HSE1 was 5′-end-labeled with IRDye700 phosphoramidites (LI-COR). Unlabeled wild-type or mutated HSE1 (Mosser et al., 1988) was used for binding competition. The double-stranded sequences of HSE1 oligonucleotides were 5′-CGAAACCCCTGGAATATTCCCGACCTGGCA-3′ and 5′-TGCCAGGTCGGGAATATTCCAGGGGTTTCG-3′ (wild-type) and 5′-CGAAACCCCTTCAATATTGTCCACCTGGCA-3′ and 5′-TGCCAGGTGGACAATATTGAAGGGGTTTCG-3′ (mutant). Statistical analysis. Data are expressed as the average ± SD of at least three independent experiments. Statistical analysis was performed with GraphPad PRISM v5.0 (GraphPad Inc., San Diego, CA) using Student's t-test or two-way ANOVA. A p <0.05 was considered statistically significant. RESULTS HSF1 Mediates ATO Induction of HSP27 and HSP70 and Protects Cells From ATO Cytotoxicity The effects of ATO on HSF1 activation are shown in Figure 1A. ATO treatment (1μM) for 5 h induced a molecular weight shift in HSF1, phosphorylation at S326 (pHSF1S326), and a concomitant increase in the expression of HSP27 and HSP70 in CGL2 cells, indicating that ATO activates HSF1 and induces the HSR (Fig. 1A). However, phosphorylation of HSF1 was not evident at S230 (pHSF1S230) and S320 (pHSF1S320), two other previously reported stimulatory phosphorylation sites (Holmberg et al., 2001; Murshid et al., 2010). This result is consistent with a previous study showing that phosphorylation of HSF1 at S326 but not other serine residues is critical for heat-induced HSP70 expression (Guettouche et al., 2005). To evaluate the role of HSF1 on ATO cytotoxicity, CGL2 cells that stably expressed wtHSF1, caHSF1, or dnHSF1 were established, and expression of each HSF1 protein was confirmed by immunoblotting (Fig. 1B). Compared with the control CGL2-pFB-Neo cells, CGL2 cells expressing wtHSF1 displayed higher levels of ATO-induced S326 phosphorylation and expression of HSP27 and 70. The caHSF1 mutant lacks the inhibitory regulatory domain and hence is transcriptionally activated under unstressed conditions (Green et al., 1995; Zuo et al., 1995). CGL2 cells expressing caHSF1 had increased amounts of the more slowly migrating caHSF1 in response to increasing concentrations of ATO and constitutive expression of HSP27 and 70. The dnHSF1 mutant, which lacks the C-terminal transactivation domain but preserves the DNA-binding and trimerization domain, antagonizes transcription from heat shock promoters and depletes intracellular HSP concentrations (Green et al., 1995; Wang et al., 2004b). Expression of dnHSF1 in CGL2 cells led to a reduction in ATO-induced expression of HSP27 and 70. These results indicated that HSF1 played a major role in ATO-induced expression of HSP27 and 70. Treatment of control CGL2-pFB-Neo cells with ATO resulted in a dose-dependent decrease in cell viability (Fig. 1C) and induction of apoptosis (Fig. 1D). Expression of wtHSF1 or caHSF1 in CGL2 cells significantly reduced this ATO-induced cell death and apoptosis. In contrast, expression of dnHSF1 in CGL2 cells considerably enhanced ATO-induced cell death and apoptosis. Thus, HSF1 is critical for maintaining cell viability in response to ATO by reducing apoptosis, and this reduction in ATO cytotoxicity may be mediated by the HSF1-dependent expression of HSPs. FIG. 1. Open in new tabDownload slide HSF1 mediates ATO induction of HSP27 and 70 and protects cells from ATO cytotoxicity. (A) ATO activates HSF1 and induces HSR. CGL2 cells were treated with 1μM ATO for the times indicated, and expression of HSF1, phosphorylated HSF1 (pHSF1), HSP27, and HSP70 was examined by immunoblotting. The symbol > indicates basal HSF1, and * indicates slowly migrating HSF1. (B) Expression and function of HSF1 in stable cell lines. Stable cell lines containing empty vector (pFB-Neo) or vectors expressing wtHSF1, caHSF1, or dnHSF1 were treated for 8 h with various concentrations of ATO and examined for expression of HSF1, pHSF1S326, HSP27, and HSP70 by immunoblotting. The symbol ← indicates endogenous HSF1, < indicates ectopically expressed HSF1, and * indicates slowly migrating ectopic HSF1. (C and D) Effects of HSF1 on ATO cytotoxicity. The same stable cell lines were treated with ATO for 72 h (C) or 32 h (D) and then analyzed for cell viability by WST-8 assay (C) or for induction of apoptosis by examining cellular levels of PARP cleavage (D). In (C), * indicates p < 0.01 compared with pFB-Neo cells, based on trend analysis by two-way ANOVA. In (D), # indicates p < 0.01 compared with untreated pFB-Neo cells, and * indicates p < 0.01 compared with ATO-treated pFB-Neo cells, as determined by Student's t-test. FIG. 1. Open in new tabDownload slide HSF1 mediates ATO induction of HSP27 and 70 and protects cells from ATO cytotoxicity. (A) ATO activates HSF1 and induces HSR. CGL2 cells were treated with 1μM ATO for the times indicated, and expression of HSF1, phosphorylated HSF1 (pHSF1), HSP27, and HSP70 was examined by immunoblotting. The symbol > indicates basal HSF1, and * indicates slowly migrating HSF1. (B) Expression and function of HSF1 in stable cell lines. Stable cell lines containing empty vector (pFB-Neo) or vectors expressing wtHSF1, caHSF1, or dnHSF1 were treated for 8 h with various concentrations of ATO and examined for expression of HSF1, pHSF1S326, HSP27, and HSP70 by immunoblotting. The symbol ← indicates endogenous HSF1, < indicates ectopically expressed HSF1, and * indicates slowly migrating ectopic HSF1. (C and D) Effects of HSF1 on ATO cytotoxicity. The same stable cell lines were treated with ATO for 72 h (C) or 32 h (D) and then analyzed for cell viability by WST-8 assay (C) or for induction of apoptosis by examining cellular levels of PARP cleavage (D). In (C), * indicates p < 0.01 compared with pFB-Neo cells, based on trend analysis by two-way ANOVA. In (D), # indicates p < 0.01 compared with untreated pFB-Neo cells, and * indicates p < 0.01 compared with ATO-treated pFB-Neo cells, as determined by Student's t-test. S326 Phosphorylation Is Required for HSF1-Mediated HSP Expression and Is Critical for Cytoprotection Against ATO S326 phosphorylation plays a critical role in heat stress–induced HSF1 activation (Guettouche et al., 2005) and was induced in ATO-treated cells (Fig. 1A). To understand the role of S326 phosphorylation in ATO cytotoxicity, CGL2 cells that were stably depleted of HSF1 (CGL2-shHSF1) were established, and the depletion efficiency was confirmed by immunoblotting (Fig. 2A). ATO-induced S326 phosphorylation of HSF1 was undetectable, and expression of HSP27 and 70 was diminished in CGL2-shHSF1 cells compared with control pLKO cells (Fig. 2A). In addition, CGL2-shHSF1 cells were more susceptible than control pLKO cells to ATO-induced cell death (Fig. 2B), caspase-9 activation (Fig. 2C), or PARP cleavage (Fig. 2D). These results indicated that HSF1 was required for ATO-induced expression of HSP27 and 70 and protected cells from ATO cytotoxicity by reducing apoptosis. FIG. 2. Open in new tabDownload slide Cells stably depleted of HSF1 have diminished levels of HSP27 and 70 and are sensitive to ATO. (A) Expression level of HSF1 in cells stably depleted of HSF1 (CGL2-shHSF1). CGL2-shHSF1 and control CGL2-pLKO cells were treated with ATO for 8 h and examined for expression of HSF1, HSP27, and HSP70 by immunoblotting. (B–D) Enhanced sensitivity of CGL2-shHSF1 cells to ATO. CGL2-shHSF1 and control CGL2-pLKO cells were treated with ATO for 72 h (B), 24 h (C), or 32 h (D) and analyzed for cell viability (B), caspase-9 activity (C), or apoptosis (D). The symbol * indicates p < 0.01 compared with control CGL2-pLKO cells, based on trend analysis by two-way ANOVA. FIG. 2. Open in new tabDownload slide Cells stably depleted of HSF1 have diminished levels of HSP27 and 70 and are sensitive to ATO. (A) Expression level of HSF1 in cells stably depleted of HSF1 (CGL2-shHSF1). CGL2-shHSF1 and control CGL2-pLKO cells were treated with ATO for 8 h and examined for expression of HSF1, HSP27, and HSP70 by immunoblotting. (B–D) Enhanced sensitivity of CGL2-shHSF1 cells to ATO. CGL2-shHSF1 and control CGL2-pLKO cells were treated with ATO for 72 h (B), 24 h (C), or 32 h (D) and analyzed for cell viability (B), caspase-9 activity (C), or apoptosis (D). The symbol * indicates p < 0.01 compared with control CGL2-pLKO cells, based on trend analysis by two-way ANOVA. Next, wtHSF1 or the S326A substitution mutant was ectopically overexpressed in CGL2-shHSF1 cells, and expression was confirmed by immunoblotting (Fig. 3A). ATO-induced expression of HSP27 and 70 was recovered by overexpressing wtHSF1 but not S326A, indicating that S326 phosphorylation of HSF1 was required for ATO induction of HSP27 and 70. In addition, ATO-induced cell death in CGL2-shHSF1 cells was reduced by ectopic expression of wtHSF1 but not by expression of S326A (Fig. 3B). These results indicated that phosphorylation of HSF1 S326 is critical for downstream expression of HSPs as well as the cytoprotective effect toward ATO cytotoxicity, with the implication that inhibition of S326 phosphorylation may enhance ATO cytotoxicity. FIG. 3. Open in new tabDownload slide Phosphorylation of HSF1 S326 is critical for ATO induction of HSP27 and 70 and the cytoprotective effect of HSF1 toward ATO. (A) Effects of HSF1 S326A substitution mutant on ATO induction of HSP27 and 70. CGL2-shHSF1 cells ectopically expressing empty vector (pFB-Neo), FLAG-tagged wtHSF1, or FLAG-tagged S326A substitution mutant were treated with ATO for 8 h and examined for expression of HSF1, FLAG, HSP27, and HSP70 by immunoblotting. (B) Effects of HSF1 S326A substitution mutant on ATO-induced cell death. The cells were treated with ATO for 72 h and then analyzed by WST-8 viability assay. Results are mean ± SD of three independent experiments. The symbol # indicates p < 0.01 compared with non-transduced cells treated with the same ATO concentration, and * indicates p < 0.01 compared with pFB-wtHSF1-transduced cells treated with the same ATO concentration, based on Student's t-test. FIG. 3. Open in new tabDownload slide Phosphorylation of HSF1 S326 is critical for ATO induction of HSP27 and 70 and the cytoprotective effect of HSF1 toward ATO. (A) Effects of HSF1 S326A substitution mutant on ATO induction of HSP27 and 70. CGL2-shHSF1 cells ectopically expressing empty vector (pFB-Neo), FLAG-tagged wtHSF1, or FLAG-tagged S326A substitution mutant were treated with ATO for 8 h and examined for expression of HSF1, FLAG, HSP27, and HSP70 by immunoblotting. (B) Effects of HSF1 S326A substitution mutant on ATO-induced cell death. The cells were treated with ATO for 72 h and then analyzed by WST-8 viability assay. Results are mean ± SD of three independent experiments. The symbol # indicates p < 0.01 compared with non-transduced cells treated with the same ATO concentration, and * indicates p < 0.01 compared with pFB-wtHSF1-transduced cells treated with the same ATO concentration, based on Student's t-test. PI103 Suppresses ATO-Induced S326 Phosphorylation and Expression of HSP70 HEK 293T cells were transiently transfected with the HSP70-luciferase reporter plasmid pGL4-A1A-1.3K (Fig. 4A). Treatment of these cells with ATO for 6 h resulted in a dose-dependent increase in expression of the HSP70 reporter (Fig. 4B). In addition to two HSEs (HSE1 and HSE2, Fig. 4A), the HSP70 promoter contains putative binding elements for the transcription factors SP1, AP-2, and ATF within ∼1.3 kb upstream of the HSP70 transcription start site as analyzed with rVISTA 2.0 (Loots and Ovcharenko, 2004). However, mutation of the two HSEs prevented ATO-induced increase in HSP70 promoter activity, even under relatively high ATO concentrations (Fig. 4B), indicating the dependence of this reporter on HSE and the specific responsiveness of this reporter to ATO-activated HSF1. FIG. 4. Open in new tabDownload slide PI103 suppresses ATO-induced HSP70 expression and phosphorylation of HSF1 S326. (A) Structure of the HSP70 promoter-luciferase reporter (pGL4-A1A-1.3K). (B) Responsiveness of pGL4-A1A-1.3K to ATO. HEK 293T cells were transiently cotransfected with pGL4-A1A-1.3K or a reporter harboring mutations in HSE1 and HSE2 along with a control Renilla luciferase reporter pGL4.7. Transfected cells were treated with ATO at the indicated concentrations for 6 h and assayed for luciferase activity. Firefly luciferase activity was normalized against cotransfected Renilla luciferase activity. (C) PI103 suppresses ATO-induced HSP70 reporter expression. HeLa cells stably transfected with pGL4-A1A-1.3K were untreated or treated for 6 h with various inhibitors in the presence or absence of 5μM ATO and then assayed for luciferase activity. The symbol # indicates a significant increase (p < 0.01) compared with untreated control cells, and * indicates a significant increase or decrease (p < 0.01) compared with cells treated with ATO alone, based on Student's t-test. (D) PI103 reduces ATO-induced HSP70 expression. Stably transfected HeLa cells were untreated or treated for 6 h with various inhibitors in the presence or absence of 3μM ATO, and messenger RNA levels of HSP70 and β-actin were determined by reverse transcription PCR. (E) PI103 inhibits phosphorylation of HSF1 S326. HeLa cells were treated for 8 h with 3μM ATO plus the indicated concentrations of PI103, NU7026, LY294002 (LY), or rapamycin, and expression of phosphorylated HSF1 (pHSF1S326) and HSP70 was examined by immunoblotting. Relative intensities of pHSF1S326 were determined by densitometric analyses, and results are mean ± SD of three independent experiments. *Indicates a significant increase or decrease (p < 0.01). FIG. 4. Open in new tabDownload slide PI103 suppresses ATO-induced HSP70 expression and phosphorylation of HSF1 S326. (A) Structure of the HSP70 promoter-luciferase reporter (pGL4-A1A-1.3K). (B) Responsiveness of pGL4-A1A-1.3K to ATO. HEK 293T cells were transiently cotransfected with pGL4-A1A-1.3K or a reporter harboring mutations in HSE1 and HSE2 along with a control Renilla luciferase reporter pGL4.7. Transfected cells were treated with ATO at the indicated concentrations for 6 h and assayed for luciferase activity. Firefly luciferase activity was normalized against cotransfected Renilla luciferase activity. (C) PI103 suppresses ATO-induced HSP70 reporter expression. HeLa cells stably transfected with pGL4-A1A-1.3K were untreated or treated for 6 h with various inhibitors in the presence or absence of 5μM ATO and then assayed for luciferase activity. The symbol # indicates a significant increase (p < 0.01) compared with untreated control cells, and * indicates a significant increase or decrease (p < 0.01) compared with cells treated with ATO alone, based on Student's t-test. (D) PI103 reduces ATO-induced HSP70 expression. Stably transfected HeLa cells were untreated or treated for 6 h with various inhibitors in the presence or absence of 3μM ATO, and messenger RNA levels of HSP70 and β-actin were determined by reverse transcription PCR. (E) PI103 inhibits phosphorylation of HSF1 S326. HeLa cells were treated for 8 h with 3μM ATO plus the indicated concentrations of PI103, NU7026, LY294002 (LY), or rapamycin, and expression of phosphorylated HSF1 (pHSF1S326) and HSP70 was examined by immunoblotting. Relative intensities of pHSF1S326 were determined by densitometric analyses, and results are mean ± SD of three independent experiments. *Indicates a significant increase or decrease (p < 0.01). HeLa cells stably expressing the same reporter (HeLa pGL4-A1A-1.3K) were then established to efficiently and reproducibly screen for modulators of stress-induced HSP70 expression. Triptolide (an HSR inhibitor) and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, an HSP90 inhibitor that can induce HSP70 expression) served as controls to inhibit (Westerheide et al., 2006) or stimulate (Kim et al., 1999) expression of the HSP70 reporter, respectively (Fig. 4C). PI103, an inhibitor of the phosphatidylinositol 3-kinase (PI3K) family, when used at increasing concentrations from 0.1 to 1μM significantly suppressed ATO induction of the HSP70 reporter (Fig. 4C). The kinase inhibitor PD98059 caused a slight increase in ATO-induced HSP70 reporter activity, and other kinase inhibitors (including Go6976, SB203580, SP600125, and U0126) had no significant effect (data not shown). The effect of PI103 on ATO induction of endogenous HSP70 was also examined by reverse transcription PCR. Figure 4D shows that simultaneous treatment of cells with PI103 and ATO considerably reduced ATO-induced expression of HSP70. In addition, PI103 significantly suppressed ATO-induced phosphorylation of HSF1 S326 (Fig. 4E). Thus, PI103 suppressed not only ATO-induced expression of the HSP70 promoter-luciferase reporter and endogenous HSP70 but also phosphorylation of HSF1 S326. Because PI103 can inhibit PI3K-p110, DNA-dependent protein kinase (DNA-PK), and mammalian target of rapamycin (mTOR), we next examined the effects of LY294002 (an inhibitor of PI3K) (Vlahos et al., 1994), NU7026 (an inhibitor of DNA-PK) (Hollick et al., 2003), and rapamycin (an allosteric inhibitor of mTOR complex 1) (Loewith et al., 2002) on ATO-induced HSP70 expression and phosphorylation of HSF1 S326. NU7026 reduced ATO-induced expression of the HSP70 reporter and endogenous HSP70 and reduced S326 phosphorylation (Fig. 4C–E), but it was less effective than PI103 even at a relatively high concentration. LY294002 and rapamycin had no effect on HSP70 expression or S326 phosphorylation. These results indicated that the PI3K/AKT and mTOR pathway might not be directly involved in ATO-induced HSP70 expression or phosphorylation of HSF1 S326. PI103 Suppresses HSF1 Transactivation To further examine how PI103 inhibits HSF1, the effects of PI103 on HSF1 nuclear translocation, DNA binding, and transactivation were examined in ATO-treated cells. Figure 5A shows that HSF1 in untreated control cells was unphosphorylated and remained in the cytosolic fraction. In contrast, when cells were treated with ATO (20μM for 4 h) or heat stress (42°C for 30 min and recovery for 4 h), HSF1 was found primarily in the nucleus and was phosphorylated at S326. Simultaneous treatment with PI103 and ATO had no significant effect on the nuclear translocation of HSF1 but notably reduced phosphorylation at S326. ATO at the concentration of 1–10μM induced a partial translocation of HSF1 to the nucleus, and PI103 did not reduced the level of ATO-induced nuclear HSF1 (data not shown). Heat stress–induced nuclear translocation of HSF1 was also not affected by the presence of PI103. These results indicated that suppression of S326 phosphorylation by PI103 did not affect HSF1 translocation into nuclei after ATO treatment or heat shock. FIG. 5. Open in new tabDownload slide PI103 suppresses HSF1 transactivation. (A and B) PI103 has no effect on HSF1 nuclear translocation or DNA binding. CGL2 cells were treated alone with ATO (20μM for 4 h), heat (42°C for 30 min and recovered for 4 h), or PI103 (1μM for 4 h), simultaneously treated with ATO plus PI103 for 4 h or sequentially treated with PI103 for 30 min followed by heat shock for 30 min and then PI103 for 4 h. Cytosolic and nuclear fractions were then prepared and analyzed (A) for HSF1 levels by immunoblotting or (B) for HSF1 binding to HSE by EMSA. In (A), β-tubulin and PARP were used as cytosolic and nuclear markers, respectively. In (B), the specificity of HSE binding was confirmed by addition of a 30-fold excess of unlabeled HSE or mutated HSE to the reaction mixture for competitive binding. (C) PI103 inhibits HSF1 transactivation. HEK 293T cells were transiently cotransfected with plasmids encoding the GAL4-HSF1 fusion protein, GAL4-luciferase reporter, and control Renilla luciferase reporter, then treated with ATO in the presence or absence of each inhibitor, and assayed for luciferase activity. Firefly luciferase activity was normalized against cotransfected Renilla luciferase activity. The symbol # indicates a significant increase (p < 0.01) compared with untreated control cells, and * indicates a significant decrease (p < 0.01) compared with cells treated with ATO alone, based on Student's t-test. FIG. 5. Open in new tabDownload slide PI103 suppresses HSF1 transactivation. (A and B) PI103 has no effect on HSF1 nuclear translocation or DNA binding. CGL2 cells were treated alone with ATO (20μM for 4 h), heat (42°C for 30 min and recovered for 4 h), or PI103 (1μM for 4 h), simultaneously treated with ATO plus PI103 for 4 h or sequentially treated with PI103 for 30 min followed by heat shock for 30 min and then PI103 for 4 h. Cytosolic and nuclear fractions were then prepared and analyzed (A) for HSF1 levels by immunoblotting or (B) for HSF1 binding to HSE by EMSA. In (A), β-tubulin and PARP were used as cytosolic and nuclear markers, respectively. In (B), the specificity of HSE binding was confirmed by addition of a 30-fold excess of unlabeled HSE or mutated HSE to the reaction mixture for competitive binding. (C) PI103 inhibits HSF1 transactivation. HEK 293T cells were transiently cotransfected with plasmids encoding the GAL4-HSF1 fusion protein, GAL4-luciferase reporter, and control Renilla luciferase reporter, then treated with ATO in the presence or absence of each inhibitor, and assayed for luciferase activity. Firefly luciferase activity was normalized against cotransfected Renilla luciferase activity. The symbol # indicates a significant increase (p < 0.01) compared with untreated control cells, and * indicates a significant decrease (p < 0.01) compared with cells treated with ATO alone, based on Student's t-test. We then examined whether PI103 inhibits HSF1 DNA-binding activity by EMSA using IRDye-labeled HSE1 as a probe. Figure 5B shows that a very low level of HSF1 DNA binding was observed in untreated control cells (lane 4), but heat shock induced a significant increase in HSF1 binding to IRDye-labeled HSE1 (lane 8), and this binding was diminished by addition of unlabeled wild-type HSE1 (lane 1) but not affected by addition of mutant HSE1 (lane 2). ATO treatment also induced significant DNA binding of HSF1 (lane 6). However, ATO-induced or heat stress–induced HSF1 DNA binding was not reduced by the presence of PI103 (compared lanes 6 and 7 and lanes 8 and 9). Thus, PI103 did not inhibit the ATO-induced HSF1 binding to the HSE of the HSP70 promoter. We then examined whether PI103 could alter the transactivation of HSF1 by using a previously reported Gal4-HSF1 fusion construct and Gal4-luciferase reporter (Shi et al., 1995). In the Gal4-HSF1 fusion protein, the DNA-binding domain of HSF1 was replaced with that of Gal4, thus allowing the analysis of HSF1 regulation downstream of DNA binding. Cells cotransfected with Gal4-HSF1 fusion construct and Gal4-luciferase reporter were treated with ATO in the presence or absence of PI103. As shown in Figure 5C, ATO significantly increased expression of the Gal4-luciferase reporter. This increase was suppressed in a dose-dependent manner by PI103 and triptolide, a compound that suppresses HSF1 transactivation (Westerheide et al., 2006). Therefore, PI103 may inhibit HSF1 by altering its transactivation activity. NU7026, but not rapamycin, also reduced ATO-induced expression of the Gal4-luciferase reporter. PI103 Enhances ATO Cytotoxicity in an HSF1-Dependent Manner To further characterize the role of PI103 inhibition of HSF1 on ATO cytotoxicity, CGL2-shHSF1 cells were treated with ATO in the presence or absence of PI103. Figure 6 shows that PI103 did not increase ATO-induced cell death in CGL2-shHSF1 cells. Ectopic overexpression of wtHSF1 in CGL2-shHSF1 cells considerably enhanced cell viability after ATO treatment, and this enhanced viability was significantly decreased by simultaneous treatment with PI103. These results indicated that PI103 enhanced ATO cytotoxicity through inhibition of HSF1. FIG. 6. Open in new tabDownload slide PI103 enhances ATO cytotoxicity. CGL2-shHSF1 and CGL2-shHSF1 cells expressing wtHSF1 were treated for 24 h with ATO in the presence or absence of 1μM PI103, and cell viability was analyzed. The symbol * indicates p < 0.01 compared with CGL2-shHSF1 cells, and # indicates p < 0.01 compared with wtHSF1-transduced cells treated with ATO alone, based on trend analysis by two-way ANOVA. FIG. 6. Open in new tabDownload slide PI103 enhances ATO cytotoxicity. CGL2-shHSF1 and CGL2-shHSF1 cells expressing wtHSF1 were treated for 24 h with ATO in the presence or absence of 1μM PI103, and cell viability was analyzed. The symbol * indicates p < 0.01 compared with CGL2-shHSF1 cells, and # indicates p < 0.01 compared with wtHSF1-transduced cells treated with ATO alone, based on trend analysis by two-way ANOVA. DISCUSSION Environmental exposure to arsenic compounds, which enter the human body principally by ingestion or inhalation, can cause acute and chronic effects in many organ systems via pathways that are inadequately understood. Arsenite promotes the activation of various signaling networks related to cell stress, including DNA damage, oxidative stress, endoplasmic reticulum stress, and proteotoxicity pathways. On the other hand, the toxicity of arsenite can be applied clinically to treat cancers, infectious diseases, and skin lesions. Therefore, identifying strategies that effectively manage the toxic effects of arsenite are pivotal to broadening its clinical utility. A variety of cytoprotective pathways are activated in response to arsenite, promoting changes in gene expression that facilitate cell survival and recovery from stress. For example, arsenite induces the transcription factors Nrf2 (Alam et al., 1999) and NFκB (Barchowsky et al., 1996), which mediate antioxidant signaling, and HSF1 (Khalil et al., 2006), which mediate HSR. Arsenite also activates the PI3K/AKT survival pathway (Tabellini et al., 2005). Modulation of these pathways may therefore prove useful in the clinical use of arsenite. Our present study demonstrated that HSF1 was required for ATO induction of HSP27 and 70 and ameliorated ATO cytotoxicity by reducing apoptosis. Among the three human members of the HSF family, HSF1 is the major stress-responsive member, as no other HSF is able to functionally substitute for HSF1 or rescue the HSR in HSF1-deficient cells (Pirkkala et al., 2001). Silencing of HSF1 diminishes the expression of HSPs and leads to destabilization of Bcl-XL, Mcl-1, and Bcl-2 in cancer cells, thereby enhancing apoptosis (Jacobs and Marnett, 2007, 2009). Inactivation of HSF1 through GSK-3β-mediated phosphorylation at S303 inhibits HSP expression and promotes apoptosis (Kazemi et al., 2010). On the other hand, HSF1 can activate the expression of multidrug resistance gene 1, thus inducing resistance to anticancer drugs (Tchenio et al., 2006). In addition, HSP27 and 70 are known to inhibit activation of caspases and hence prevent apoptosis (Calderwood et al., 2006). These results support our findings that inhibiting HSF1 activation enhanced ATO cytotoxicity by diminishing HSR and facilitating apoptosis. Therefore, in cancer treatment, the use of ATO in combination with HSF1 inhibitors may enhance therapeutic efficacy while minimizing the dose of ATO and thus its toxic side effects. Our results showed that ATO led to significant phosphorylation of HSF1 at S326 but not at S230 and S320. We also demonstrated that this phosphorylation played a critical role in HSF1 activation in ATO-treated cells, including downstream transactivation of HSPs and cytoprotection to ATO toxicity. Many posttranslational modifications have been reported to either repress or stimulate the activation of HSF1 (Anckar and Sistonen, 2011). Phosphopeptide mapping has demonstrated that HSF1 is phosphorylated at 12 serine residues (S121, S230, S292, S303, S307, S314, S319, S326, S344, S363, S419, and S444), but only the mutation at S326 significantly reduces heat-induced HSP70 expression (Guettouche et al., 2005), indicating that S326 phosphorylation plays a critical role in the activation of HSF1 by heat stress. Several studies have shown that posttranslational modifications in the regulatory domain of HSF1 (residues 221–383) during stress override the inhibitory effects, such as phosphorylation, 14-3-3 binding, and sumoylation, and stimulate HSF1 transactivation (Murshid et al., 2010; Wang et al., 2004a). ATO-induced S326 phosphorylation may override all other inhibitory modifications of HSF1 and facilitate its transactivation. In this model, inhibition of S326 phosphorylation of HSF1 would diminish its function in HSP induction and cytoprotection. Our results show that suppression of S326 phosphorylation by PI103 effectively reduced HSF1 transactivation but not nuclear translocation or DNA binding in ATO-treated cells, indicating that S326 phosphorylation may directly control HSF1 transactivation. This is consistent with a previous study showing that S326A significantly attenuates the ability of HSF1 to induce HSP70 expression after heat stress but does not alter heat-induced nuclear translocation and DNA binding (Guettouche et al., 2005). The kinase responsible for phosphorylation of HSF1 S326 remains unknown. PI103 is an ATP-competitive inhibitor of members of the PI3K family that inhibits DNA-PK, PI3K-p110α, mTORC1, PI3K-p110δ, mTORC2, PI3K-p110β, and PI3K-p110γ with a half-maximal inhibitory concentration of 2, 8, 20, 48, 83, 88, and 150nM, respectively (Fan et al., 2006). In our current study, PI103 suppressed ATO-induced S326 phosphorylation and transactivation of HSF1. Furthermore, LY294002 and rapamycin, which inhibit the PI3K/AKT and mTOR pathways, respectively, and may have small effects on DNA-PK (Workman et al., 2010), had no significant effect on ATO-induced HSP70 expression, whereas NU7026 (an inhibitor of DNA-PK; Hollick et al., 2003) suppressed ATO-induced S326 phosphorylation and HSP70 expression. These results suggest that DNA-PK may be involved in phosphorylation of HSF1 at S326. It has been reported that DNA-PK interacts with HSF1 (Huang et al., 1997), and that DNA-PK-deficient cell lines are 10-fold more sensitive to heat-induced apoptosis than matched DNA-PK-proficient lines (Nueda et al., 1999). In addition, increased expression of the DNA-PK catalytic subunit or its regulatory elements Ku70/Ku80 results in upregulation of HSP70 and 90, and loss of the DNA-PK catalytic subunit leads to attenuated expression of HSP70 and 90 and enhances cell death (Kang et al., 2008). These results indicate that DNA-PK may positively regulate HSF1 activation. Further detailed studies are necessary to dissect this interaction and may provide information regarding the regulation of HSF1 activation by ATO. FUNDING Academia Sinica and a grant from National Science Council (NSC99-2320-B-001-008-MY3), Taiwan. We thank the National RNAi Core Facility Platform (Institute of Molecular Biology/Genomic Research Center, Academia Sinica), which is supported by the National Core Facility Program for Biotechnology Grants of the National Science Council of Taiwan, for technical support in the preparation of HSF1 shRNA. We also thank the Core Facility of the Institute of Cellular and Organismic Biology, Academia Sinica, for assistance with DNA sequencing. References Alam J Stewart D Touchard C Boinapally S Choi AM Cook JL Nrf2, a Cap‘n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene J. Biol. Chem. 1999 274 26071 26078 Google Scholar Crossref Search ADS PubMed WorldCat Anckar J Sistonen L Regulation of HSF1 function in the heat stress response: Implications in aging and disease Annu. Rev. Biochem. 2011 80 1089 1115 Google Scholar Crossref Search ADS PubMed WorldCat Barbey JT Pezzullo JC Soignet SL Effect of arsenic trioxide on QT interval in patients with advanced malignancies J. Clin. Oncol. 2003 21 3609 3615 Google Scholar Crossref Search ADS PubMed WorldCat Barchowsky A Dudek EJ Treadwell MD Wetterhahn KE Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells Free Radic. Biol. Med. 1996 21 783 790 Google Scholar Crossref Search ADS PubMed WorldCat Calderwood SK Khaleque MA Sawyer DB Ciocca DR Heat shock proteins in cancer: Chaperones of tumorigenesis Trends Biochem. Sci. 2006 31 164 172 Google Scholar Crossref Search ADS PubMed WorldCat Dai C Whitesell L Rogers AB Lindquist S Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis Cell 2007 130 1005 1018 Google Scholar Crossref Search ADS PubMed WorldCat Del Razo LM Quintanilla-Vega B Brambila-Colombres E Calderon-Aranda ES Manno M Albores A Stress proteins induced by arsenic Toxicol. Appl. Pharmacol. 2001 177 132 148 Google Scholar Crossref Search ADS PubMed WorldCat Dilda PJ Hogg PJ Arsenical-based cancer drugs Cancer Treat. Rev. 2007 33 542 564 Google Scholar Crossref Search ADS PubMed WorldCat Douer D Tallman MS Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies J. Clin. Oncol. 2005 23 2396 2410 Google Scholar Crossref Search ADS PubMed WorldCat Fan QW Knight ZA Goldenberg DD Yu W Mostov KE Stokoe D Shokat KM Weiss WA A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma Cancer Cell 2006 9 341 349 Google Scholar Crossref Search ADS PubMed WorldCat Fang F Chang R Yang L Heat shock factor 1 promotes invasion and metastasis of hepatocellular carcinoma in vitro and in vivo Cancer 2012 118 1782 1794 Google Scholar Crossref Search ADS PubMed WorldCat Green M Schuetz TJ Sullivan EK Kingston RE A heat shock-responsive domain of human HSF1 that regulates transcription activation domain function Mol. Cell. Biol. 1995 15 3354 3362 Google Scholar Crossref Search ADS PubMed WorldCat Guettouche T Boellmann F Lane WS Voellmy R Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress BMC Biochem. 2005 6 4 Google Scholar Crossref Search ADS PubMed WorldCat Hollick JJ Golding BT Hardcastle IR Martin N Richardson C Rigoreau LJ Smith GC Griffin RJ 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK) Bioorg. Med. Chem. Lett. 2003 13 3083 3086 Google Scholar Crossref Search ADS PubMed WorldCat Holmberg CI Hietakangas V Mikhailov A Rantanen JO Kallio M Meinander A Hellman J Morrice N MacKintosh C Morimoto RI et al. Phosphorylation of serine 230 promotes inducible transcriptional activity of heat shock factor 1 EMBO J. 2001 20 3800 3810 Google Scholar Crossref Search ADS PubMed WorldCat Holmberg CI Tran SE Eriksson JE Sistonen L Multisite phosphorylation provides sophisticated regulation of transcription factors Trends Biochem. Sci. 2002 27 619 627 Google Scholar Crossref Search ADS PubMed WorldCat Huang J Nueda A Yoo S Dynan WS Heat shock transcription factor 1 binds selectively in vitro to Ku protein and the catalytic subunit of the DNA-dependent protein kinase J. Biol. Chem. 1997 272 26009 26016 Google Scholar Crossref Search ADS PubMed WorldCat International Agency for Research on Cancer Arsenic in drinking water International Agency for Research on Cancer Monographs on the Evaluation of Carcinogenic Risk to Humans. Some Drinking Water Disinfectants and Contaminants, Including Arsenic 2004 Lyon, France IARC 269 477 Google Scholar Google Preview OpenURL Placeholder Text WorldCat COPAC Google Scholar Jacobs AT Marnett LJ Heat shock factor 1 attenuates 4-hydroxynonenal-mediated apoptosis: Critical role for heat shock protein 70 induction and stabilization of Bcl-XL J. Biol. Chem. 2007 282 33412 33420 Google Scholar Crossref Search ADS PubMed WorldCat Jacobs AT Marnett LJ HSF1-mediated BAG3 expression attenuates apoptosis in 4-hydroxynonenal-treated colon cancer cells via stabilization of anti-apoptotic Bcl-2 proteins J. Biol. Chem. 2009 284 9176 9183 Google Scholar Crossref Search ADS PubMed WorldCat Kakadiya R Wu YC Dong H Kuo HH Yih LH Chou TC Su TL Novel 2-substituted quinolin-4-yl-benzenesulfonate derivatives: Synthesis, antiproliferative activity, and inhibition of cellular tubulin polymerization ChemMedChem 2011 6 1119 1129 Google Scholar Crossref Search ADS PubMed WorldCat Kang MJ Jung SM Kim MJ Bae JH Kim HB Kim JY Park SJ Song HS Kim DW Kang CD et al. DNA-dependent protein kinase is involved in heat shock protein-mediated accumulation of hypoxia-inducible factor-1alpha in hypoxic preconditioned HepG2 cells FEBS J 2008 275 5969 5981 Google Scholar Crossref Search ADS PubMed WorldCat Kazemi Z Chang H Haserodt S McKen C Zachara NE O-linked beta-N-acetylglucosamine (O-GlcNAc) regulates stress-induced heat shock protein expression in a GSK-3beta-dependent manner J. Biol. Chem. 2010 285 39096 39107 Google Scholar Crossref Search ADS PubMed WorldCat Khalil S Luciano J Chen W Liu AY Dynamic regulation and involvement of the heat shock transcriptional response in arsenic carcinogenesis J. Cell. Physiol. 2006 207 562 569 Google Scholar Crossref Search ADS PubMed WorldCat Kim HR Kang HS Kim HD Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells IUBMB Life 1999 48 429 433 Google Scholar Crossref Search ADS PubMed WorldCat Kim SA Yoon JH Lee SH Ahn SG Polo-like kinase 1 phosphorylates heat shock transcription factor 1 and mediates its nuclear translocation during heat stress J. Biol. Chem. 2005 280 12653 12657 Google Scholar Crossref Search ADS PubMed WorldCat Laemmli UK Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 1970 227 680 685 Google Scholar Crossref Search ADS PubMed WorldCat Liu J Zhang D Mi X Xia Q Yu Y Zuo Z Guo W Zhao X Cao J Yang Q et al. p27 suppresses arsenite-induced Hsp27/Hsp70 expression through inhibiting JNK2/c-Jun- and HSF-1-dependent pathways J. Biol. Chem. 2010 285 26058 26065 Google Scholar Crossref Search ADS PubMed WorldCat Loewith R Jacinto E Wullschleger S Lorberg A Crespo JL Bonenfant D Oppliger W Jenoe P Hall MN Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control Mol. Cell 2002 10 457 468 Google Scholar Crossref Search ADS PubMed WorldCat Loots GG Ovcharenko I rVISTA 2.0: Evolutionary analysis of transcription factor binding sites Nucleic Acids Res. 2004 32 (Web Server issue), W217–W221 OpenURL Placeholder Text WorldCat Meng L Gabai VL Sherman MY Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis Oncogene 2010 29 5204 5213 Google Scholar Crossref Search ADS PubMed WorldCat Miller WH Jr Schipper HM Lee JS Singer J Waxman S Mechanisms of action of arsenic trioxide Cancer Res. 2002 62 3893 3903 Google Scholar PubMed OpenURL Placeholder Text WorldCat Min JN Huang L Zimonjic DB Moskophidis D Mivechi NF Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors Oncogene 2007 26 5086 5097 Google Scholar Crossref Search ADS PubMed WorldCat Mosser DD Theodorakis NG Morimoto RI Coordinate changes in heat shock element-binding activity and HSP70 gene transcription rates in human cells Mol. Cell. Biol. 1988 8 4736 4744 Google Scholar Crossref Search ADS PubMed WorldCat Murgo AJ Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies Oncologist 2001 6 Suppl. 2 22 28 Google Scholar Crossref Search ADS PubMed WorldCat Murshid A Chou SD Prince T Zhang Y Bharti A Calderwood SK Protein kinase A binds and activates heat shock factor 1 PLoS One 2010 5 e13830 Google Scholar Crossref Search ADS PubMed WorldCat Nueda A Hudson F Mivechi NF Dynan WS DNA-dependent protein kinase protects against heat-induced apoptosis J. Biol. Chem. 1999 274 14988 14996 Google Scholar Crossref Search ADS PubMed WorldCat Pelicano H Carew JS McQueen TJ Andreeff M Plunkett W Keating MJ Huang P Targeting Hsp90 by 17-AAG in leukemia cells: Mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C Leukemia 2006 20 610 619 Google Scholar Crossref Search ADS PubMed WorldCat Phillips PA Dudeja V McCarroll JA Borja-Cacho D Dawra RK Grizzle WE Vickers SM Saluja AK Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70 Cancer Res. 2007 67 9407 9416 Google Scholar Crossref Search ADS PubMed WorldCat Pirkkala L Nykanen P Sistonen L Roles of the heat shock transcription factors in regulation of the heat shock response and beyond FASEB J. 2001 15 1118 1131 Google Scholar Crossref Search ADS PubMed WorldCat Richter K Haslbeck M Buchner J The heat shock response: Life on the verge of death Mol. Cell 2010 40 253 266 Google Scholar Crossref Search ADS PubMed WorldCat Rossi A Ciafre S Balsamo M Pierimarchi P Santoro MG Targeting the heat shock factor 1 by RNA interference: A potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer Cancer Res. 2006 66 7678 7685 Google Scholar Crossref Search ADS PubMed WorldCat Sambrook J Fritsch EF Maniatis T Molecular Cloning: A Laboratory Manual 1989 Cold Spring Harbor, NY Cold Spring Harbor Laboratory Google Scholar Google Preview OpenURL Placeholder Text WorldCat COPAC Santagata S Hu R Lin NU Mendillo ML Collins LC Hankinson SE Schnitt SJ Whitesell L Tamimi RM Lindquist S et al. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer Proc. Natl. Acad. Sci. U.S.A. 2011 108 18378 18383 Google Scholar Crossref Search ADS PubMed WorldCat Shi Y Kroeger PE Morimoto RI The carboxyl-terminal transactivation domain of heat shock factor 1 is negatively regulated and stress responsive Mol. Cell. Biol. 1995 15 4309 4318 Google Scholar Crossref Search ADS PubMed WorldCat Soignet SL Maslak P Wang ZG Jhanwar S Calleja E Dardashti LJ Corso D DeBlasio A Gabrilove J Scheinberg DA et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide N. Engl. J. Med. 1998 339 1341 1348 Google Scholar Crossref Search ADS PubMed WorldCat Stanbridge EJ Flandermeyer RR Daniels DW Nelson-Rees WA Specific chromosome loss associated with the expression of tumorigenicity in human cell hybrids Somatic Cell Genet. 1981 7 699 712 Google Scholar Crossref Search ADS PubMed WorldCat Straif K Benbrahim-Tallaa L Baan R Grosse Y Secretan B El Ghissassi F Bouvard V Guha N Freeman C Galichet L et al. A review of human carcinogens—part C: Metals, arsenic, dusts, and fibres Lancet Oncol. 2009 10 453 454 Google Scholar Crossref Search ADS PubMed WorldCat Tabellini G Cappellini A Tazzari PL Fala F Billi AM Manzoli L Cocco L Martelli AM Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells J. Cell. Physiol. 2005 202 623 634 Google Scholar Crossref Search ADS PubMed WorldCat Taylor BF McNeely SC Miller HL States JC Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization Toxicol. Appl. Pharmacol. 2008 230 235 246 Google Scholar Crossref Search ADS PubMed WorldCat Tchenio T Havard M Martinez LA Dautry F Heat shock-independent induction of multidrug resistance by heat shock factor 1 Mol. Cell. Biol. 2006 26 580 591 Google Scholar Crossref Search ADS PubMed WorldCat Vlahos CJ Matter WF Hui KY Brown RF A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) J. Biol. Chem. 1994 269 5241 5248 Google Scholar PubMed OpenURL Placeholder Text WorldCat Vuky J Yu R Schwartz L Motzer RJ Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma Invest. New Drugs 2002 20 327 330 Google Scholar Crossref Search ADS PubMed WorldCat Wang JH Yao MZ Gu JF Sun LY Shen YF Liu XY Blocking HSF1 by dominant-negative mutant to sensitize tumor cells to hyperthermia Biochem. Biophys. Res. Commun. 2002 290 1454 1461 Google Scholar Crossref Search ADS PubMed WorldCat Wang X Grammatikakis N Siganou A Stevenson MA Calderwood SK Interactions between extracellular signal-regulated protein kinase 1, 14-3-3epsilon, and heat shock factor 1 during stress J. Biol. Chem. 2004a 279 49460 49469 Google Scholar Crossref Search ADS WorldCat Wang Y Theriault JR He H Gong J Calderwood SK Expression of a dominant negative heat shock factor-1 construct inhibits aneuploidy in prostate carcinoma cells J. Biol. Chem. 2004b 279 32651 32659 Google Scholar Crossref Search ADS WorldCat Westerheide SD Kawahara TL Orton K Morimoto RI Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death J. Biol. Chem. 2006 281 9616 9622 Google Scholar Crossref Search ADS PubMed WorldCat Wetzler M Earp JC Brady MT Keng MK Jusko WJ Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity—Pharmacodynamic drug-drug interaction modeling Clin. Cancer Res. 2007 13 2261 2270 Google Scholar Crossref Search ADS PubMed WorldCat Whitesell L Lindquist S Inhibiting the transcription factor HSF1 as an anticancer strategy Expert Opin. Ther. Targets 2009 13 469 478 Google Scholar Crossref Search ADS PubMed WorldCat Workman P Clarke PA Raynaud FI van Montfort RL Drugging the PI3 kinome: From chemical tools to drugs in the clinic Cancer Res. 2010 70 2146 2157 Google Scholar Crossref Search ADS PubMed WorldCat Wu YC Yen WY Lee TC Yih LH Heat shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic trioxide-induced mitotic apoptosis Toxicol. Appl. Pharmacol. 2009 236 231 238 Google Scholar Crossref Search ADS PubMed WorldCat Wu YC Yen WY Ho HY Su TL Yih LH Glyfoline induces mitotic catastrophe and apoptosis in cancer cells Int. J. Cancer 2010 126 1017 1028 Google Scholar PubMed OpenURL Placeholder Text WorldCat Yih LH Hsueh SW Luu WS Chiu TH Lee TC Arsenite induces prominent mitotic arrest via inhibition of G2 checkpoint activation in CGL-2 cells Carcinogenesis 2005 26 53 63 Google Scholar Crossref Search ADS PubMed WorldCat Zuo J Rungger D Voellmy R Multiple layers of regulation of human heat shock transcription factor 1 Mol. Cell. Biol. 1995 15 4319 4330 Google Scholar Crossref Search ADS PubMed WorldCat © The Author 2012. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please email: [email protected] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Toxicological Sciences Oxford University Press

Inhibition of the Heat Shock Response by PI103 Enhances the Cytotoxicity of Arsenic Trioxide

Download PDF
11 pages

Loading next page...
 
/lp/oxford-university-press/inhibition-of-the-heat-shock-response-by-pi103-enhances-the-39ixqNgCu0

References (69)

Publisher
Oxford University Press
Copyright
© The Author 2012. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please email: [email protected]
Subject
Molecular Toxicology
ISSN
1096-6080
eISSN
1096-0929
DOI
10.1093/toxsci/kfs130
pmid
22496356
Publisher site
See Article on Publisher Site

Abstract

Abstract Heat shock factor 1 (HSF1) is a key regulator of the cytoprotective and anti-apoptotic heat shock response and can be activated by arsenite. Inhibition of HSF1 activation may therefore enhance the cytotoxicity of arsenic trioxide (ATO). We show that ATO induced HSF1 phosphorylation at serine 326 (S326) and induced HSF1-dependent expression of heat shock proteins (HSPs) 27 and 70 in cultured cells. HSF1 significantly reduced cell sensitivity to ATO by reducing apoptosis. Disruption of HSF1 function not only reduced ATO induction of HSP27 and 70 but also enhanced ATO cytotoxicity by elevating apoptosis. These results reveal that HSF1 activation and the resulting induction of HSPs may protect cells from ATO cytotoxicity. The diminished expression of HSPs and hypersensitivity to ATO in cells stably depleted of HSF1 was rescued by ectopic expression of wild-type HSF1 but not an S326A substitution mutant, indicating that phosphorylation at S326 was critical for the protective effect of HSF1. Simultaneous treatment of cells with ATO and PI103, an inhibitor of members of the phosphatidylinositol 3-kinase (PI3K) family, suppressed not only ATO-induced expression of an HSP70 promoter-reporter construct and endogenous HSP70 but also phosphorylation of HSF1 S326. PI103 considerably reduced HSF1 transactivation in ATO-treated cells but had only a limited effect on HSF1 nuclear translocation and DNA binding. Furthermore, PI103 enhanced ATO cytotoxicity in an HSF1-dependent manner. Thus, inhibition of S326 phosphorylation by PI103 blocks the transactivation of HSF1 and may consequently suppress ATO induction of the heat shock response and sensitize cells to ATO. arsenic trioxide, cytotoxicity, heat shock factor 1, heat shock response, apoptosis Arsenic trioxide (ATO) is used to treat acute promyelocytic leukemia by inducing apoptosis and partial differentiation (Miller et al., 2002; Soignet et al., 1998). However, the use of ATO as a single agent in clinical trials against solid tumors refractory to current therapies was found to be ineffective or highly toxic (Dilda and Hogg, 2007; Murgo, 2001; Vuky et al., 2002). In addition, chronic exposure to inorganic arsenic is carcinogenic (International Agency for Research on Cancer, 2004; Straif et al., 2009). ATO can prolong the QT interval and lead to torsade de pointes (Barbey et al., 2003), and the U.S. FDA-approved formulation of ATO induces acute promyelocytic leukemia differentiation syndrome, neuropathy, hepatotoxicity, and hematologic toxicity in patients with a variety of hematologic and solid malignancies (Douer and Tallman, 2005). Hence, mechanistic studies that can better elucidate the mechanism of action of ATO are necessary to reduce its toxicity and/or improve clinical outcomes. Heat shock factor 1 (HSF1) is the master transcriptional regulator of the cellular response to heat and a wide variety of other stresses (Anckar and Sistonen, 2011). In response to stress, the inactive monomer HSF1 trimerizes and binds to heat shock elements (HSEs) of target genes, including those encoding heat shock protein (HSP) 27, HSP70, and HSP90, thereby driving their expression (Anckar and Sistonen, 2011; Holmberg et al., 2002). The resulting rapid and robust induction of the heat shock response (HSR) leads to a universal adaptation and protection mechanism against adverse environmental stresses and many pathophysiological conditions (Richter et al., 2010). Either the level of HSF1 or its nuclear localization can be elevated in cancer cell lines and tumor tissues (Fang et al., 2011; Santagata et al., 2011). Several reports have demonstrated that loss of HSF1 function prevents oncogenesis (Dai et al., 2007; Meng et al., 2010; Min et al., 2007) or causes a dramatic increase in sensitivity of cancer cells to hyperthermia or chemotherapy, leading to massive apoptosis (Phillips et al., 2007; Rossi et al., 2006; Wang et al., 2002; Westerheide et al., 2006). Thus, inhibiting HSF1 activation may sensitize cancer cells to death and augment chemotherapy-induced apoptosis (Whitesell and Lindquist, 2009). Moreover, a prominent feature of HSF1 is that its conversion into a transcriptionally active trimer occurs concurrently with hyperphosphorylation of serine (S) residues. Following heat stress, phosphorylation at S230 or S326 promotes HSF1 transactivation (Guettouche et al., 2005; Holmberg et al., 2001), whereas phosphorylation at S320 or S419 mediates its nuclear translocation (Kim et al., 2005; Murshid et al., 2010). In addition, S326 has been demonstrated to be the most critical serine residue for HSF1 transactivation after heat stress (Guettouche et al., 2005). The kinases responsible for phosphorylation of HSF1 have not been definitively identified. Nonetheless, inhibition of HSF1 phosphorylation may prevent its complete activation, slow cancer progression, and/or enhance therapeutic efficacy. Arsenic compounds are known to induce the expression of HSPs (Del Razo et al., 2001). The induction of HSR is a sensitive indicator of arsenic exposure and may be involved in the tumorigenicity of arsenic (Khalil et al., 2006). Suppression of arsenite-induced expression of HSP27 and HSP70 may account for the function of p27, a member of a family of cyclin-dependent kinase inhibitors and a putative tumor suppressor that induces cell cycle arrest (Liu et al., 2010). In addition, inhibition of HSP70 or HSP90 effectively enhances ATO cytotoxicity (Pelicano et al., 2006; Taylor et al., 2008; Wetzler et al., 2007; Wu et al., 2009). Given that induction of HSPs depends primarily on HSF1, it is critical to have a firm understanding of how HSF1 is activated by ATO and whether inhibition of HSF1 increases ATO cytotoxicity. MATERIALS AND METHODS Cell culture and reagents. HeLa and HEK 293T cells were obtained from the American Type Culture Collection (Manassas, VA). CGL2 cells (a HeLa cell/normal human fibroblast hybrid; Stanbridge et al., 1981) were kindly provided by Dr. E. J. Stanbridge (University of California, Irvine). Cells were routinely maintained in Dulbecco's Modified Eagle's Medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen), 0.37% sodium bicarbonate, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C in a humidified atmosphere containing 10% CO2 and were passaged twice per week. ATO (Sigma-Aldrich, St Louis, MO) was freshly dissolved in 0.1 N NaOH to make a 10mM stock solution before use. PI103, LY294002, NU7026, rapamycin, Go6976, SB203580, SP600125, and U0126 were obtained from Calbiochem (Merck KGaA, Darmstadt, Germany), dissolved in dimethyl sulfoxide to make 10mM stock solutions, and stored in aliquots at −20°C. Establishment of stable HSF1-deficient CGL2 cells. Stable depletion of HSF1 was achieved by transduction of CGL2 cells with VSV-G-pseudotyped lentivirus-based short hairpin RNA (shRNA). Viral supernatants–containing empty vector (pLKO) or HSF1-specific shRNA (TRCN7480) were obtained from the National RNAi Core Facility Platform (Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taipei, Taiwan). CGL2 cells were transduced with pLKO- or shRNA-containing supernatant (multiplicity of infection = 3) in growth medium supplemented with 10 μg/ml polybrene. At 24 h post-transduction, 2 μg/ml puromycin was added to culture medium to select for stable clones (CGL2-pLKO and CGL2-shHSF1). Depletion efficiency was examined by immunoblotting. Expression vectors and reporter constructs. To generate a retroviral plasmid–encoding wild-type HSF1 (wtHSF1, residues 1–529), full-length HSF1 complementary DNA (cDNA) was amplified by PCR using primers in which restriction sites for EcoRI and XhoI had been created (5′-GGAATTCGCCACCATGGATCTGCCCGTGGGCCC-3′ and 5′-CCGCTCGAGCTAGGAGACAGTGGGGTCCTTGGC-3′; GenBank accession number NM_005526). Products were digested with EcoRI and XhoI and then subcloned into the corresponding sites of the retroviral pFB-Neo vector (Stratagene/Agilent Technologies, La Jolla, CA). HSF1 constructs with different deletions or the S326A substitution mutation were created using the QuickChange Site-Directed Mutagenesis Kit (Stratagene) following the manufacturer's instructions. Constitutively active HSF1 (caHSF1) was obtained by deleting amino acid residues 202–316 (Zuo et al., 1995), and dominant negative HSF1 (dnHSF1) was obtained by truncating after residue 361 as described (Green et al., 1995). A GAL4-HSF1 fusion construct was obtained by inserting human HSF1 (residues 124–503) into the Gal4 DNA-binding domain–containing pFA-CMV vector (Stratagene) as described (Shi et al., 1995). To construct a human HSP70 promoter-luciferase reporter pGL4-A1A-1.3K, a fragment from −1310 to +155 bp relative to the transcription start site of HSP70 (HSPA1A) was cloned by PCR amplification from a BAC clone (RP11-1104F14; Invitrogen) using primers 5′-ACACGGTGAAACCTCGTCTC-3′ and 5′-TGAGATTGGGGGCTGGAAAC-3′. PCR products were cloned into the pJET1.2/blunt vector (Fermentas, Glen Burnie, MD) and then subcloned into the pGL4.15[luc2P/Hygro] vector (Promega, Madison, WI) with the aid of BglII and BamHI digestion. Two putative HSF1-binding elements (HSE1 and HSE2, both within ∼1.3 kb upstream of the HSP70 transcription start site) were mutated as described (Mosser et al., 1988) using site-directed mutagenesis (HSE1: −109CTGGAATATTCCCG−96 to −109CTTCAATATTGTCC−96; HSE2: −192CTGGAGAGTTCTGA−179 to −192CTTCAGAGTTGTGC−179). All constructs were confirmed by DNA sequencing. Retroviral gene delivery and establishment of stable cell lines. To generate virus particles containing each HSF1 expression construct, HEK 293T cells were cotransfected with pVPack-GP, pVPack-VSV-G (Stratagene), and either pFB-Neo (empty vector) or one of the pFB-HSF1 constructs (pFB-wtHSF1, pFB-caHSF1, pFB-dnHSF1, or pFB-S326A) using Lipofectamine 2000 (Invitrogen). At 48 h post-transfection, supernatant containing retrovirus with the specific HSF1 construct was collected, filtered through a 0.2-μm filter, and used without further purification. CGL2 and CGL2-shHSF1 cells were transduced with retrovirus-containing supernatants in growth medium supplemented with 10 μg/ml diethylaminoethyl-dextran (Sigma). At 24 h post-transduction, 1 mg/ml neomycin (Invitrogen) was added to the culture medium to select for stable cell lines (CGL2-pFB-Neo, CGL2-wtHSF1, CGL2-caHSF1, CGL2-dnHSF1, CGL2-shHSF1-pFB-Neo, CGL2-shHSF1-wtHSF1, or CGL2-shHSF1-S326A). The expression level of each construct was examined by immunoblotting. Cytotoxicity assay. Cells were seeded in at 2 × 104 cells per well in a 24-well plate, cultured for 24 h, and then treated with drugs for 24–72 h. Cytotoxicity was assayed by determining viable cell numbers using methylthiazole tetrazolium (WST-8; Cell Count Kit 8; Dojindo Molecular Technologies, Inc., Gaithersburg, MD) as described (Kakadiya et al., 2011). Analysis of apoptosis. Apoptosis was quantified by measuring the activity of caspase-9 using the CaspaTag Caspase 9 In Situ Assay kit (Chemicon). Briefly, untreated or ATO-treated cells were incubated with a carboxyfluorescein-labeled fluoromethyl ketone peptide, which is membrane permeable and binds covalently to a reactive cysteine residue of active caspase-9. The bound fluorescent reagent within cells was then measured using a flow cytometer (FACSCanto II; BD Biosciences, San Jose, CA). The caspase-9 activity was expressed as the mean fluorescence of 10,000 cells. Apoptosis was also quantified by measuring the level of cleaved poly(ADP-ribose) polymerase (PARP) in individual cells as described (Wu et al., 2010). Luciferase reporter assay. HEK 293T cells, known to display high transfection efficiencies, were transiently cotransfected with a wild-type or HSE-mutated pGL4-A1A-1.3K reporter plasmid along with a control Renilla luciferase reporter (pGL4.7; Promega) using Lipofectamine 2000. At 5 h post-transfection, cells were replated at 3 × 104 cells per well in 24-well plates and incubated for another 24 h. Cells were treated with ATO for 6 h, and luciferase activity was measured using the Dual-Glo assay system (Promega). The pGL4-A1A-1.3K stable cell line was generated by transfecting HeLa cells, which also manifest high transfection efficiencies, with pGL4-A1A-1.3K using Lipofectamine 2000. Colonies resistant to hygromycin (0.2 mg/ml) were tested for induction of luciferase expression 6 h after ATO treatment, and the colony with the highest luciferase level was selected for further studies. Cells were plated at 3 × 104 cells per well in 24-well plates 24 h prior to drug treatment. Luciferase assays were performed using the Bright-Glo assay system. To measure the transactivation activity of HSF1, HEK 293T cells were transiently cotransfected with plasmids encoding the GAL4-HSF1 fusion protein and GAL4-luciferase reporter (pFR-Luc; Stratagene) along with a control Renilla luciferase reporter (pGL4.7; Promega) using Lipofectamine 2000. After ATO treatment, luciferase assays were performed using the Dual-Glo assay system. Reverse transcription PCR. Cellular RNA was extracted with Trizol reagent (Invitrogen), and 5 μg was reverse transcribed with Superscript III (Invitrogen) and oligo-dT (Promega). A linear range of input cDNA was determined empirically via a twofold dilution series in 26- to 28-cycle reactions in the presence of DreamTaq DNA polymerase (Fermentas). PCR products were run on 1% Tris/borate/EDTA agarose gels (Sambrook et al., 1989), stained with SYBR Gold (Invitrogen), and quantified using GeneTools (Syngene, Cambridge, UK). β-actin was used as an internal control. The primer sets were 5′-CTACAAGGGGGAGACCAAGG-3′ and 5′-TTCACCAGCCTGTTGTCAAA-3′ (for HSP70) and 5′-GCACTCTTCCAGCCTTCC-3′ and 5′-GCGCTCAGGAGGAGCAAT-3′ (for β-actin). Preparation of cell lysates. Total cell lysates were prepared by boiling cells directly in Laemmli sample buffer (Laemmli, 1970). For fractionation of cytosol and nuclei, cells on plates were washed with ice-cold PBS, lysed for 10 min at 4°C in a 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (10mM HEPES, pH 7.9, 10mM KCl, 0.1mM EDTA, 0.4% [vol/vol] NP-40, 1mM phenylmethylsulfonyl fluoride, 2mM leupeptin, 2mM aprotinin, 2mM pepstatin, 25mM sodium fluoride, and 1mM sodium orthovanadate), and then scraped off the plates. The cytosolic fraction was obtained by centrifuging the cell lysate at 15,000 × g for 10 min and collecting the clear supernatant. The nuclear pellet was resuspended and further extracted for 2 h at 4°C in another HEPES buffer (20mM HEPES, pH 7.9, 0.4M NaCl, 1mM EDTA, 10% glycerol, 1mM phenylmethylsulfonyl fluoride, 2mM leupeptin, 2mM aprotinin, 2mM pepstatin, 25mM sodium fluoride, and 1mM sodium orthovanadate). The nuclear fraction was obtained by centrifuging at 15,000 × g for 10 min and collecting the supernatant. The cytosolic and nuclear fractions were subjected to immunoblot analysis and electrophoretic mobility shift assay (EMSA). Immunoblot analysis. Cell lysates were resolved by 8 or 12% SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes. Specific proteins were detected as described (Yih et al., 2005) using antibodies against HSF1, HSF1 phosphorylated at S230, HSP27, HSP70, and PARP (Santa Cruz Biotechnology, Santa Cruz, CA), HSF1 phosphorylated at S320 or S326 (Epitomics, Burlingame, CA), and FLAG and α-tubulin (Sigma). β-actin was detected with anti-β-actin (Chemicon, Temecula, CA) and was used as a loading control. Relative levels of HSF1 phosphorylation were quantified using GeneTools (Syngene) and determined by normalizing with the intensities of β-actin. Electrophoretic mobility shift assay. HSF1 binding to a consensus HSE from the human HSP70 promoter (HSE1) was analyzed by EMSA. Briefly, 2 μg nuclear extract was mixed with 20-pmol IRDye-labeled HSE1 oligonucleotide and 0.5 μg poly(dI-dC) (Sigma) in Tris buffer (10mM Tris, pH 7.8, 50mM NaCl, 1mM EDTA, 0.5mM dithiothreitol, and 5% glycerol) in a final volume of 25 μl. After a 20-min binding reaction at 25°C, an Orange Loading Dye (LI-COR, Lincoln, NE) was added, and the reaction products were loaded directly onto a 4% native polyacrylamide gel (50mM Tris, pH 7.5, 0.38M glycine, and 2mM EDTA). Gels were run at room temperature for 30 min at 80 V and then scanned under the Odyssey Infrared Imaging System (LI-COR). HSE1 was 5′-end-labeled with IRDye700 phosphoramidites (LI-COR). Unlabeled wild-type or mutated HSE1 (Mosser et al., 1988) was used for binding competition. The double-stranded sequences of HSE1 oligonucleotides were 5′-CGAAACCCCTGGAATATTCCCGACCTGGCA-3′ and 5′-TGCCAGGTCGGGAATATTCCAGGGGTTTCG-3′ (wild-type) and 5′-CGAAACCCCTTCAATATTGTCCACCTGGCA-3′ and 5′-TGCCAGGTGGACAATATTGAAGGGGTTTCG-3′ (mutant). Statistical analysis. Data are expressed as the average ± SD of at least three independent experiments. Statistical analysis was performed with GraphPad PRISM v5.0 (GraphPad Inc., San Diego, CA) using Student's t-test or two-way ANOVA. A p <0.05 was considered statistically significant. RESULTS HSF1 Mediates ATO Induction of HSP27 and HSP70 and Protects Cells From ATO Cytotoxicity The effects of ATO on HSF1 activation are shown in Figure 1A. ATO treatment (1μM) for 5 h induced a molecular weight shift in HSF1, phosphorylation at S326 (pHSF1S326), and a concomitant increase in the expression of HSP27 and HSP70 in CGL2 cells, indicating that ATO activates HSF1 and induces the HSR (Fig. 1A). However, phosphorylation of HSF1 was not evident at S230 (pHSF1S230) and S320 (pHSF1S320), two other previously reported stimulatory phosphorylation sites (Holmberg et al., 2001; Murshid et al., 2010). This result is consistent with a previous study showing that phosphorylation of HSF1 at S326 but not other serine residues is critical for heat-induced HSP70 expression (Guettouche et al., 2005). To evaluate the role of HSF1 on ATO cytotoxicity, CGL2 cells that stably expressed wtHSF1, caHSF1, or dnHSF1 were established, and expression of each HSF1 protein was confirmed by immunoblotting (Fig. 1B). Compared with the control CGL2-pFB-Neo cells, CGL2 cells expressing wtHSF1 displayed higher levels of ATO-induced S326 phosphorylation and expression of HSP27 and 70. The caHSF1 mutant lacks the inhibitory regulatory domain and hence is transcriptionally activated under unstressed conditions (Green et al., 1995; Zuo et al., 1995). CGL2 cells expressing caHSF1 had increased amounts of the more slowly migrating caHSF1 in response to increasing concentrations of ATO and constitutive expression of HSP27 and 70. The dnHSF1 mutant, which lacks the C-terminal transactivation domain but preserves the DNA-binding and trimerization domain, antagonizes transcription from heat shock promoters and depletes intracellular HSP concentrations (Green et al., 1995; Wang et al., 2004b). Expression of dnHSF1 in CGL2 cells led to a reduction in ATO-induced expression of HSP27 and 70. These results indicated that HSF1 played a major role in ATO-induced expression of HSP27 and 70. Treatment of control CGL2-pFB-Neo cells with ATO resulted in a dose-dependent decrease in cell viability (Fig. 1C) and induction of apoptosis (Fig. 1D). Expression of wtHSF1 or caHSF1 in CGL2 cells significantly reduced this ATO-induced cell death and apoptosis. In contrast, expression of dnHSF1 in CGL2 cells considerably enhanced ATO-induced cell death and apoptosis. Thus, HSF1 is critical for maintaining cell viability in response to ATO by reducing apoptosis, and this reduction in ATO cytotoxicity may be mediated by the HSF1-dependent expression of HSPs. FIG. 1. Open in new tabDownload slide HSF1 mediates ATO induction of HSP27 and 70 and protects cells from ATO cytotoxicity. (A) ATO activates HSF1 and induces HSR. CGL2 cells were treated with 1μM ATO for the times indicated, and expression of HSF1, phosphorylated HSF1 (pHSF1), HSP27, and HSP70 was examined by immunoblotting. The symbol > indicates basal HSF1, and * indicates slowly migrating HSF1. (B) Expression and function of HSF1 in stable cell lines. Stable cell lines containing empty vector (pFB-Neo) or vectors expressing wtHSF1, caHSF1, or dnHSF1 were treated for 8 h with various concentrations of ATO and examined for expression of HSF1, pHSF1S326, HSP27, and HSP70 by immunoblotting. The symbol ← indicates endogenous HSF1, < indicates ectopically expressed HSF1, and * indicates slowly migrating ectopic HSF1. (C and D) Effects of HSF1 on ATO cytotoxicity. The same stable cell lines were treated with ATO for 72 h (C) or 32 h (D) and then analyzed for cell viability by WST-8 assay (C) or for induction of apoptosis by examining cellular levels of PARP cleavage (D). In (C), * indicates p < 0.01 compared with pFB-Neo cells, based on trend analysis by two-way ANOVA. In (D), # indicates p < 0.01 compared with untreated pFB-Neo cells, and * indicates p < 0.01 compared with ATO-treated pFB-Neo cells, as determined by Student's t-test. FIG. 1. Open in new tabDownload slide HSF1 mediates ATO induction of HSP27 and 70 and protects cells from ATO cytotoxicity. (A) ATO activates HSF1 and induces HSR. CGL2 cells were treated with 1μM ATO for the times indicated, and expression of HSF1, phosphorylated HSF1 (pHSF1), HSP27, and HSP70 was examined by immunoblotting. The symbol > indicates basal HSF1, and * indicates slowly migrating HSF1. (B) Expression and function of HSF1 in stable cell lines. Stable cell lines containing empty vector (pFB-Neo) or vectors expressing wtHSF1, caHSF1, or dnHSF1 were treated for 8 h with various concentrations of ATO and examined for expression of HSF1, pHSF1S326, HSP27, and HSP70 by immunoblotting. The symbol ← indicates endogenous HSF1, < indicates ectopically expressed HSF1, and * indicates slowly migrating ectopic HSF1. (C and D) Effects of HSF1 on ATO cytotoxicity. The same stable cell lines were treated with ATO for 72 h (C) or 32 h (D) and then analyzed for cell viability by WST-8 assay (C) or for induction of apoptosis by examining cellular levels of PARP cleavage (D). In (C), * indicates p < 0.01 compared with pFB-Neo cells, based on trend analysis by two-way ANOVA. In (D), # indicates p < 0.01 compared with untreated pFB-Neo cells, and * indicates p < 0.01 compared with ATO-treated pFB-Neo cells, as determined by Student's t-test. S326 Phosphorylation Is Required for HSF1-Mediated HSP Expression and Is Critical for Cytoprotection Against ATO S326 phosphorylation plays a critical role in heat stress–induced HSF1 activation (Guettouche et al., 2005) and was induced in ATO-treated cells (Fig. 1A). To understand the role of S326 phosphorylation in ATO cytotoxicity, CGL2 cells that were stably depleted of HSF1 (CGL2-shHSF1) were established, and the depletion efficiency was confirmed by immunoblotting (Fig. 2A). ATO-induced S326 phosphorylation of HSF1 was undetectable, and expression of HSP27 and 70 was diminished in CGL2-shHSF1 cells compared with control pLKO cells (Fig. 2A). In addition, CGL2-shHSF1 cells were more susceptible than control pLKO cells to ATO-induced cell death (Fig. 2B), caspase-9 activation (Fig. 2C), or PARP cleavage (Fig. 2D). These results indicated that HSF1 was required for ATO-induced expression of HSP27 and 70 and protected cells from ATO cytotoxicity by reducing apoptosis. FIG. 2. Open in new tabDownload slide Cells stably depleted of HSF1 have diminished levels of HSP27 and 70 and are sensitive to ATO. (A) Expression level of HSF1 in cells stably depleted of HSF1 (CGL2-shHSF1). CGL2-shHSF1 and control CGL2-pLKO cells were treated with ATO for 8 h and examined for expression of HSF1, HSP27, and HSP70 by immunoblotting. (B–D) Enhanced sensitivity of CGL2-shHSF1 cells to ATO. CGL2-shHSF1 and control CGL2-pLKO cells were treated with ATO for 72 h (B), 24 h (C), or 32 h (D) and analyzed for cell viability (B), caspase-9 activity (C), or apoptosis (D). The symbol * indicates p < 0.01 compared with control CGL2-pLKO cells, based on trend analysis by two-way ANOVA. FIG. 2. Open in new tabDownload slide Cells stably depleted of HSF1 have diminished levels of HSP27 and 70 and are sensitive to ATO. (A) Expression level of HSF1 in cells stably depleted of HSF1 (CGL2-shHSF1). CGL2-shHSF1 and control CGL2-pLKO cells were treated with ATO for 8 h and examined for expression of HSF1, HSP27, and HSP70 by immunoblotting. (B–D) Enhanced sensitivity of CGL2-shHSF1 cells to ATO. CGL2-shHSF1 and control CGL2-pLKO cells were treated with ATO for 72 h (B), 24 h (C), or 32 h (D) and analyzed for cell viability (B), caspase-9 activity (C), or apoptosis (D). The symbol * indicates p < 0.01 compared with control CGL2-pLKO cells, based on trend analysis by two-way ANOVA. Next, wtHSF1 or the S326A substitution mutant was ectopically overexpressed in CGL2-shHSF1 cells, and expression was confirmed by immunoblotting (Fig. 3A). ATO-induced expression of HSP27 and 70 was recovered by overexpressing wtHSF1 but not S326A, indicating that S326 phosphorylation of HSF1 was required for ATO induction of HSP27 and 70. In addition, ATO-induced cell death in CGL2-shHSF1 cells was reduced by ectopic expression of wtHSF1 but not by expression of S326A (Fig. 3B). These results indicated that phosphorylation of HSF1 S326 is critical for downstream expression of HSPs as well as the cytoprotective effect toward ATO cytotoxicity, with the implication that inhibition of S326 phosphorylation may enhance ATO cytotoxicity. FIG. 3. Open in new tabDownload slide Phosphorylation of HSF1 S326 is critical for ATO induction of HSP27 and 70 and the cytoprotective effect of HSF1 toward ATO. (A) Effects of HSF1 S326A substitution mutant on ATO induction of HSP27 and 70. CGL2-shHSF1 cells ectopically expressing empty vector (pFB-Neo), FLAG-tagged wtHSF1, or FLAG-tagged S326A substitution mutant were treated with ATO for 8 h and examined for expression of HSF1, FLAG, HSP27, and HSP70 by immunoblotting. (B) Effects of HSF1 S326A substitution mutant on ATO-induced cell death. The cells were treated with ATO for 72 h and then analyzed by WST-8 viability assay. Results are mean ± SD of three independent experiments. The symbol # indicates p < 0.01 compared with non-transduced cells treated with the same ATO concentration, and * indicates p < 0.01 compared with pFB-wtHSF1-transduced cells treated with the same ATO concentration, based on Student's t-test. FIG. 3. Open in new tabDownload slide Phosphorylation of HSF1 S326 is critical for ATO induction of HSP27 and 70 and the cytoprotective effect of HSF1 toward ATO. (A) Effects of HSF1 S326A substitution mutant on ATO induction of HSP27 and 70. CGL2-shHSF1 cells ectopically expressing empty vector (pFB-Neo), FLAG-tagged wtHSF1, or FLAG-tagged S326A substitution mutant were treated with ATO for 8 h and examined for expression of HSF1, FLAG, HSP27, and HSP70 by immunoblotting. (B) Effects of HSF1 S326A substitution mutant on ATO-induced cell death. The cells were treated with ATO for 72 h and then analyzed by WST-8 viability assay. Results are mean ± SD of three independent experiments. The symbol # indicates p < 0.01 compared with non-transduced cells treated with the same ATO concentration, and * indicates p < 0.01 compared with pFB-wtHSF1-transduced cells treated with the same ATO concentration, based on Student's t-test. PI103 Suppresses ATO-Induced S326 Phosphorylation and Expression of HSP70 HEK 293T cells were transiently transfected with the HSP70-luciferase reporter plasmid pGL4-A1A-1.3K (Fig. 4A). Treatment of these cells with ATO for 6 h resulted in a dose-dependent increase in expression of the HSP70 reporter (Fig. 4B). In addition to two HSEs (HSE1 and HSE2, Fig. 4A), the HSP70 promoter contains putative binding elements for the transcription factors SP1, AP-2, and ATF within ∼1.3 kb upstream of the HSP70 transcription start site as analyzed with rVISTA 2.0 (Loots and Ovcharenko, 2004). However, mutation of the two HSEs prevented ATO-induced increase in HSP70 promoter activity, even under relatively high ATO concentrations (Fig. 4B), indicating the dependence of this reporter on HSE and the specific responsiveness of this reporter to ATO-activated HSF1. FIG. 4. Open in new tabDownload slide PI103 suppresses ATO-induced HSP70 expression and phosphorylation of HSF1 S326. (A) Structure of the HSP70 promoter-luciferase reporter (pGL4-A1A-1.3K). (B) Responsiveness of pGL4-A1A-1.3K to ATO. HEK 293T cells were transiently cotransfected with pGL4-A1A-1.3K or a reporter harboring mutations in HSE1 and HSE2 along with a control Renilla luciferase reporter pGL4.7. Transfected cells were treated with ATO at the indicated concentrations for 6 h and assayed for luciferase activity. Firefly luciferase activity was normalized against cotransfected Renilla luciferase activity. (C) PI103 suppresses ATO-induced HSP70 reporter expression. HeLa cells stably transfected with pGL4-A1A-1.3K were untreated or treated for 6 h with various inhibitors in the presence or absence of 5μM ATO and then assayed for luciferase activity. The symbol # indicates a significant increase (p < 0.01) compared with untreated control cells, and * indicates a significant increase or decrease (p < 0.01) compared with cells treated with ATO alone, based on Student's t-test. (D) PI103 reduces ATO-induced HSP70 expression. Stably transfected HeLa cells were untreated or treated for 6 h with various inhibitors in the presence or absence of 3μM ATO, and messenger RNA levels of HSP70 and β-actin were determined by reverse transcription PCR. (E) PI103 inhibits phosphorylation of HSF1 S326. HeLa cells were treated for 8 h with 3μM ATO plus the indicated concentrations of PI103, NU7026, LY294002 (LY), or rapamycin, and expression of phosphorylated HSF1 (pHSF1S326) and HSP70 was examined by immunoblotting. Relative intensities of pHSF1S326 were determined by densitometric analyses, and results are mean ± SD of three independent experiments. *Indicates a significant increase or decrease (p < 0.01). FIG. 4. Open in new tabDownload slide PI103 suppresses ATO-induced HSP70 expression and phosphorylation of HSF1 S326. (A) Structure of the HSP70 promoter-luciferase reporter (pGL4-A1A-1.3K). (B) Responsiveness of pGL4-A1A-1.3K to ATO. HEK 293T cells were transiently cotransfected with pGL4-A1A-1.3K or a reporter harboring mutations in HSE1 and HSE2 along with a control Renilla luciferase reporter pGL4.7. Transfected cells were treated with ATO at the indicated concentrations for 6 h and assayed for luciferase activity. Firefly luciferase activity was normalized against cotransfected Renilla luciferase activity. (C) PI103 suppresses ATO-induced HSP70 reporter expression. HeLa cells stably transfected with pGL4-A1A-1.3K were untreated or treated for 6 h with various inhibitors in the presence or absence of 5μM ATO and then assayed for luciferase activity. The symbol # indicates a significant increase (p < 0.01) compared with untreated control cells, and * indicates a significant increase or decrease (p < 0.01) compared with cells treated with ATO alone, based on Student's t-test. (D) PI103 reduces ATO-induced HSP70 expression. Stably transfected HeLa cells were untreated or treated for 6 h with various inhibitors in the presence or absence of 3μM ATO, and messenger RNA levels of HSP70 and β-actin were determined by reverse transcription PCR. (E) PI103 inhibits phosphorylation of HSF1 S326. HeLa cells were treated for 8 h with 3μM ATO plus the indicated concentrations of PI103, NU7026, LY294002 (LY), or rapamycin, and expression of phosphorylated HSF1 (pHSF1S326) and HSP70 was examined by immunoblotting. Relative intensities of pHSF1S326 were determined by densitometric analyses, and results are mean ± SD of three independent experiments. *Indicates a significant increase or decrease (p < 0.01). HeLa cells stably expressing the same reporter (HeLa pGL4-A1A-1.3K) were then established to efficiently and reproducibly screen for modulators of stress-induced HSP70 expression. Triptolide (an HSR inhibitor) and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, an HSP90 inhibitor that can induce HSP70 expression) served as controls to inhibit (Westerheide et al., 2006) or stimulate (Kim et al., 1999) expression of the HSP70 reporter, respectively (Fig. 4C). PI103, an inhibitor of the phosphatidylinositol 3-kinase (PI3K) family, when used at increasing concentrations from 0.1 to 1μM significantly suppressed ATO induction of the HSP70 reporter (Fig. 4C). The kinase inhibitor PD98059 caused a slight increase in ATO-induced HSP70 reporter activity, and other kinase inhibitors (including Go6976, SB203580, SP600125, and U0126) had no significant effect (data not shown). The effect of PI103 on ATO induction of endogenous HSP70 was also examined by reverse transcription PCR. Figure 4D shows that simultaneous treatment of cells with PI103 and ATO considerably reduced ATO-induced expression of HSP70. In addition, PI103 significantly suppressed ATO-induced phosphorylation of HSF1 S326 (Fig. 4E). Thus, PI103 suppressed not only ATO-induced expression of the HSP70 promoter-luciferase reporter and endogenous HSP70 but also phosphorylation of HSF1 S326. Because PI103 can inhibit PI3K-p110, DNA-dependent protein kinase (DNA-PK), and mammalian target of rapamycin (mTOR), we next examined the effects of LY294002 (an inhibitor of PI3K) (Vlahos et al., 1994), NU7026 (an inhibitor of DNA-PK) (Hollick et al., 2003), and rapamycin (an allosteric inhibitor of mTOR complex 1) (Loewith et al., 2002) on ATO-induced HSP70 expression and phosphorylation of HSF1 S326. NU7026 reduced ATO-induced expression of the HSP70 reporter and endogenous HSP70 and reduced S326 phosphorylation (Fig. 4C–E), but it was less effective than PI103 even at a relatively high concentration. LY294002 and rapamycin had no effect on HSP70 expression or S326 phosphorylation. These results indicated that the PI3K/AKT and mTOR pathway might not be directly involved in ATO-induced HSP70 expression or phosphorylation of HSF1 S326. PI103 Suppresses HSF1 Transactivation To further examine how PI103 inhibits HSF1, the effects of PI103 on HSF1 nuclear translocation, DNA binding, and transactivation were examined in ATO-treated cells. Figure 5A shows that HSF1 in untreated control cells was unphosphorylated and remained in the cytosolic fraction. In contrast, when cells were treated with ATO (20μM for 4 h) or heat stress (42°C for 30 min and recovery for 4 h), HSF1 was found primarily in the nucleus and was phosphorylated at S326. Simultaneous treatment with PI103 and ATO had no significant effect on the nuclear translocation of HSF1 but notably reduced phosphorylation at S326. ATO at the concentration of 1–10μM induced a partial translocation of HSF1 to the nucleus, and PI103 did not reduced the level of ATO-induced nuclear HSF1 (data not shown). Heat stress–induced nuclear translocation of HSF1 was also not affected by the presence of PI103. These results indicated that suppression of S326 phosphorylation by PI103 did not affect HSF1 translocation into nuclei after ATO treatment or heat shock. FIG. 5. Open in new tabDownload slide PI103 suppresses HSF1 transactivation. (A and B) PI103 has no effect on HSF1 nuclear translocation or DNA binding. CGL2 cells were treated alone with ATO (20μM for 4 h), heat (42°C for 30 min and recovered for 4 h), or PI103 (1μM for 4 h), simultaneously treated with ATO plus PI103 for 4 h or sequentially treated with PI103 for 30 min followed by heat shock for 30 min and then PI103 for 4 h. Cytosolic and nuclear fractions were then prepared and analyzed (A) for HSF1 levels by immunoblotting or (B) for HSF1 binding to HSE by EMSA. In (A), β-tubulin and PARP were used as cytosolic and nuclear markers, respectively. In (B), the specificity of HSE binding was confirmed by addition of a 30-fold excess of unlabeled HSE or mutated HSE to the reaction mixture for competitive binding. (C) PI103 inhibits HSF1 transactivation. HEK 293T cells were transiently cotransfected with plasmids encoding the GAL4-HSF1 fusion protein, GAL4-luciferase reporter, and control Renilla luciferase reporter, then treated with ATO in the presence or absence of each inhibitor, and assayed for luciferase activity. Firefly luciferase activity was normalized against cotransfected Renilla luciferase activity. The symbol # indicates a significant increase (p < 0.01) compared with untreated control cells, and * indicates a significant decrease (p < 0.01) compared with cells treated with ATO alone, based on Student's t-test. FIG. 5. Open in new tabDownload slide PI103 suppresses HSF1 transactivation. (A and B) PI103 has no effect on HSF1 nuclear translocation or DNA binding. CGL2 cells were treated alone with ATO (20μM for 4 h), heat (42°C for 30 min and recovered for 4 h), or PI103 (1μM for 4 h), simultaneously treated with ATO plus PI103 for 4 h or sequentially treated with PI103 for 30 min followed by heat shock for 30 min and then PI103 for 4 h. Cytosolic and nuclear fractions were then prepared and analyzed (A) for HSF1 levels by immunoblotting or (B) for HSF1 binding to HSE by EMSA. In (A), β-tubulin and PARP were used as cytosolic and nuclear markers, respectively. In (B), the specificity of HSE binding was confirmed by addition of a 30-fold excess of unlabeled HSE or mutated HSE to the reaction mixture for competitive binding. (C) PI103 inhibits HSF1 transactivation. HEK 293T cells were transiently cotransfected with plasmids encoding the GAL4-HSF1 fusion protein, GAL4-luciferase reporter, and control Renilla luciferase reporter, then treated with ATO in the presence or absence of each inhibitor, and assayed for luciferase activity. Firefly luciferase activity was normalized against cotransfected Renilla luciferase activity. The symbol # indicates a significant increase (p < 0.01) compared with untreated control cells, and * indicates a significant decrease (p < 0.01) compared with cells treated with ATO alone, based on Student's t-test. We then examined whether PI103 inhibits HSF1 DNA-binding activity by EMSA using IRDye-labeled HSE1 as a probe. Figure 5B shows that a very low level of HSF1 DNA binding was observed in untreated control cells (lane 4), but heat shock induced a significant increase in HSF1 binding to IRDye-labeled HSE1 (lane 8), and this binding was diminished by addition of unlabeled wild-type HSE1 (lane 1) but not affected by addition of mutant HSE1 (lane 2). ATO treatment also induced significant DNA binding of HSF1 (lane 6). However, ATO-induced or heat stress–induced HSF1 DNA binding was not reduced by the presence of PI103 (compared lanes 6 and 7 and lanes 8 and 9). Thus, PI103 did not inhibit the ATO-induced HSF1 binding to the HSE of the HSP70 promoter. We then examined whether PI103 could alter the transactivation of HSF1 by using a previously reported Gal4-HSF1 fusion construct and Gal4-luciferase reporter (Shi et al., 1995). In the Gal4-HSF1 fusion protein, the DNA-binding domain of HSF1 was replaced with that of Gal4, thus allowing the analysis of HSF1 regulation downstream of DNA binding. Cells cotransfected with Gal4-HSF1 fusion construct and Gal4-luciferase reporter were treated with ATO in the presence or absence of PI103. As shown in Figure 5C, ATO significantly increased expression of the Gal4-luciferase reporter. This increase was suppressed in a dose-dependent manner by PI103 and triptolide, a compound that suppresses HSF1 transactivation (Westerheide et al., 2006). Therefore, PI103 may inhibit HSF1 by altering its transactivation activity. NU7026, but not rapamycin, also reduced ATO-induced expression of the Gal4-luciferase reporter. PI103 Enhances ATO Cytotoxicity in an HSF1-Dependent Manner To further characterize the role of PI103 inhibition of HSF1 on ATO cytotoxicity, CGL2-shHSF1 cells were treated with ATO in the presence or absence of PI103. Figure 6 shows that PI103 did not increase ATO-induced cell death in CGL2-shHSF1 cells. Ectopic overexpression of wtHSF1 in CGL2-shHSF1 cells considerably enhanced cell viability after ATO treatment, and this enhanced viability was significantly decreased by simultaneous treatment with PI103. These results indicated that PI103 enhanced ATO cytotoxicity through inhibition of HSF1. FIG. 6. Open in new tabDownload slide PI103 enhances ATO cytotoxicity. CGL2-shHSF1 and CGL2-shHSF1 cells expressing wtHSF1 were treated for 24 h with ATO in the presence or absence of 1μM PI103, and cell viability was analyzed. The symbol * indicates p < 0.01 compared with CGL2-shHSF1 cells, and # indicates p < 0.01 compared with wtHSF1-transduced cells treated with ATO alone, based on trend analysis by two-way ANOVA. FIG. 6. Open in new tabDownload slide PI103 enhances ATO cytotoxicity. CGL2-shHSF1 and CGL2-shHSF1 cells expressing wtHSF1 were treated for 24 h with ATO in the presence or absence of 1μM PI103, and cell viability was analyzed. The symbol * indicates p < 0.01 compared with CGL2-shHSF1 cells, and # indicates p < 0.01 compared with wtHSF1-transduced cells treated with ATO alone, based on trend analysis by two-way ANOVA. DISCUSSION Environmental exposure to arsenic compounds, which enter the human body principally by ingestion or inhalation, can cause acute and chronic effects in many organ systems via pathways that are inadequately understood. Arsenite promotes the activation of various signaling networks related to cell stress, including DNA damage, oxidative stress, endoplasmic reticulum stress, and proteotoxicity pathways. On the other hand, the toxicity of arsenite can be applied clinically to treat cancers, infectious diseases, and skin lesions. Therefore, identifying strategies that effectively manage the toxic effects of arsenite are pivotal to broadening its clinical utility. A variety of cytoprotective pathways are activated in response to arsenite, promoting changes in gene expression that facilitate cell survival and recovery from stress. For example, arsenite induces the transcription factors Nrf2 (Alam et al., 1999) and NFκB (Barchowsky et al., 1996), which mediate antioxidant signaling, and HSF1 (Khalil et al., 2006), which mediate HSR. Arsenite also activates the PI3K/AKT survival pathway (Tabellini et al., 2005). Modulation of these pathways may therefore prove useful in the clinical use of arsenite. Our present study demonstrated that HSF1 was required for ATO induction of HSP27 and 70 and ameliorated ATO cytotoxicity by reducing apoptosis. Among the three human members of the HSF family, HSF1 is the major stress-responsive member, as no other HSF is able to functionally substitute for HSF1 or rescue the HSR in HSF1-deficient cells (Pirkkala et al., 2001). Silencing of HSF1 diminishes the expression of HSPs and leads to destabilization of Bcl-XL, Mcl-1, and Bcl-2 in cancer cells, thereby enhancing apoptosis (Jacobs and Marnett, 2007, 2009). Inactivation of HSF1 through GSK-3β-mediated phosphorylation at S303 inhibits HSP expression and promotes apoptosis (Kazemi et al., 2010). On the other hand, HSF1 can activate the expression of multidrug resistance gene 1, thus inducing resistance to anticancer drugs (Tchenio et al., 2006). In addition, HSP27 and 70 are known to inhibit activation of caspases and hence prevent apoptosis (Calderwood et al., 2006). These results support our findings that inhibiting HSF1 activation enhanced ATO cytotoxicity by diminishing HSR and facilitating apoptosis. Therefore, in cancer treatment, the use of ATO in combination with HSF1 inhibitors may enhance therapeutic efficacy while minimizing the dose of ATO and thus its toxic side effects. Our results showed that ATO led to significant phosphorylation of HSF1 at S326 but not at S230 and S320. We also demonstrated that this phosphorylation played a critical role in HSF1 activation in ATO-treated cells, including downstream transactivation of HSPs and cytoprotection to ATO toxicity. Many posttranslational modifications have been reported to either repress or stimulate the activation of HSF1 (Anckar and Sistonen, 2011). Phosphopeptide mapping has demonstrated that HSF1 is phosphorylated at 12 serine residues (S121, S230, S292, S303, S307, S314, S319, S326, S344, S363, S419, and S444), but only the mutation at S326 significantly reduces heat-induced HSP70 expression (Guettouche et al., 2005), indicating that S326 phosphorylation plays a critical role in the activation of HSF1 by heat stress. Several studies have shown that posttranslational modifications in the regulatory domain of HSF1 (residues 221–383) during stress override the inhibitory effects, such as phosphorylation, 14-3-3 binding, and sumoylation, and stimulate HSF1 transactivation (Murshid et al., 2010; Wang et al., 2004a). ATO-induced S326 phosphorylation may override all other inhibitory modifications of HSF1 and facilitate its transactivation. In this model, inhibition of S326 phosphorylation of HSF1 would diminish its function in HSP induction and cytoprotection. Our results show that suppression of S326 phosphorylation by PI103 effectively reduced HSF1 transactivation but not nuclear translocation or DNA binding in ATO-treated cells, indicating that S326 phosphorylation may directly control HSF1 transactivation. This is consistent with a previous study showing that S326A significantly attenuates the ability of HSF1 to induce HSP70 expression after heat stress but does not alter heat-induced nuclear translocation and DNA binding (Guettouche et al., 2005). The kinase responsible for phosphorylation of HSF1 S326 remains unknown. PI103 is an ATP-competitive inhibitor of members of the PI3K family that inhibits DNA-PK, PI3K-p110α, mTORC1, PI3K-p110δ, mTORC2, PI3K-p110β, and PI3K-p110γ with a half-maximal inhibitory concentration of 2, 8, 20, 48, 83, 88, and 150nM, respectively (Fan et al., 2006). In our current study, PI103 suppressed ATO-induced S326 phosphorylation and transactivation of HSF1. Furthermore, LY294002 and rapamycin, which inhibit the PI3K/AKT and mTOR pathways, respectively, and may have small effects on DNA-PK (Workman et al., 2010), had no significant effect on ATO-induced HSP70 expression, whereas NU7026 (an inhibitor of DNA-PK; Hollick et al., 2003) suppressed ATO-induced S326 phosphorylation and HSP70 expression. These results suggest that DNA-PK may be involved in phosphorylation of HSF1 at S326. It has been reported that DNA-PK interacts with HSF1 (Huang et al., 1997), and that DNA-PK-deficient cell lines are 10-fold more sensitive to heat-induced apoptosis than matched DNA-PK-proficient lines (Nueda et al., 1999). In addition, increased expression of the DNA-PK catalytic subunit or its regulatory elements Ku70/Ku80 results in upregulation of HSP70 and 90, and loss of the DNA-PK catalytic subunit leads to attenuated expression of HSP70 and 90 and enhances cell death (Kang et al., 2008). These results indicate that DNA-PK may positively regulate HSF1 activation. Further detailed studies are necessary to dissect this interaction and may provide information regarding the regulation of HSF1 activation by ATO. FUNDING Academia Sinica and a grant from National Science Council (NSC99-2320-B-001-008-MY3), Taiwan. We thank the National RNAi Core Facility Platform (Institute of Molecular Biology/Genomic Research Center, Academia Sinica), which is supported by the National Core Facility Program for Biotechnology Grants of the National Science Council of Taiwan, for technical support in the preparation of HSF1 shRNA. We also thank the Core Facility of the Institute of Cellular and Organismic Biology, Academia Sinica, for assistance with DNA sequencing. References Alam J Stewart D Touchard C Boinapally S Choi AM Cook JL Nrf2, a Cap‘n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene J. Biol. Chem. 1999 274 26071 26078 Google Scholar Crossref Search ADS PubMed WorldCat Anckar J Sistonen L Regulation of HSF1 function in the heat stress response: Implications in aging and disease Annu. Rev. Biochem. 2011 80 1089 1115 Google Scholar Crossref Search ADS PubMed WorldCat Barbey JT Pezzullo JC Soignet SL Effect of arsenic trioxide on QT interval in patients with advanced malignancies J. Clin. Oncol. 2003 21 3609 3615 Google Scholar Crossref Search ADS PubMed WorldCat Barchowsky A Dudek EJ Treadwell MD Wetterhahn KE Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells Free Radic. Biol. Med. 1996 21 783 790 Google Scholar Crossref Search ADS PubMed WorldCat Calderwood SK Khaleque MA Sawyer DB Ciocca DR Heat shock proteins in cancer: Chaperones of tumorigenesis Trends Biochem. Sci. 2006 31 164 172 Google Scholar Crossref Search ADS PubMed WorldCat Dai C Whitesell L Rogers AB Lindquist S Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis Cell 2007 130 1005 1018 Google Scholar Crossref Search ADS PubMed WorldCat Del Razo LM Quintanilla-Vega B Brambila-Colombres E Calderon-Aranda ES Manno M Albores A Stress proteins induced by arsenic Toxicol. Appl. Pharmacol. 2001 177 132 148 Google Scholar Crossref Search ADS PubMed WorldCat Dilda PJ Hogg PJ Arsenical-based cancer drugs Cancer Treat. Rev. 2007 33 542 564 Google Scholar Crossref Search ADS PubMed WorldCat Douer D Tallman MS Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies J. Clin. Oncol. 2005 23 2396 2410 Google Scholar Crossref Search ADS PubMed WorldCat Fan QW Knight ZA Goldenberg DD Yu W Mostov KE Stokoe D Shokat KM Weiss WA A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma Cancer Cell 2006 9 341 349 Google Scholar Crossref Search ADS PubMed WorldCat Fang F Chang R Yang L Heat shock factor 1 promotes invasion and metastasis of hepatocellular carcinoma in vitro and in vivo Cancer 2012 118 1782 1794 Google Scholar Crossref Search ADS PubMed WorldCat Green M Schuetz TJ Sullivan EK Kingston RE A heat shock-responsive domain of human HSF1 that regulates transcription activation domain function Mol. Cell. Biol. 1995 15 3354 3362 Google Scholar Crossref Search ADS PubMed WorldCat Guettouche T Boellmann F Lane WS Voellmy R Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress BMC Biochem. 2005 6 4 Google Scholar Crossref Search ADS PubMed WorldCat Hollick JJ Golding BT Hardcastle IR Martin N Richardson C Rigoreau LJ Smith GC Griffin RJ 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK) Bioorg. Med. Chem. Lett. 2003 13 3083 3086 Google Scholar Crossref Search ADS PubMed WorldCat Holmberg CI Hietakangas V Mikhailov A Rantanen JO Kallio M Meinander A Hellman J Morrice N MacKintosh C Morimoto RI et al. Phosphorylation of serine 230 promotes inducible transcriptional activity of heat shock factor 1 EMBO J. 2001 20 3800 3810 Google Scholar Crossref Search ADS PubMed WorldCat Holmberg CI Tran SE Eriksson JE Sistonen L Multisite phosphorylation provides sophisticated regulation of transcription factors Trends Biochem. Sci. 2002 27 619 627 Google Scholar Crossref Search ADS PubMed WorldCat Huang J Nueda A Yoo S Dynan WS Heat shock transcription factor 1 binds selectively in vitro to Ku protein and the catalytic subunit of the DNA-dependent protein kinase J. Biol. Chem. 1997 272 26009 26016 Google Scholar Crossref Search ADS PubMed WorldCat International Agency for Research on Cancer Arsenic in drinking water International Agency for Research on Cancer Monographs on the Evaluation of Carcinogenic Risk to Humans. Some Drinking Water Disinfectants and Contaminants, Including Arsenic 2004 Lyon, France IARC 269 477 Google Scholar Google Preview OpenURL Placeholder Text WorldCat COPAC Google Scholar Jacobs AT Marnett LJ Heat shock factor 1 attenuates 4-hydroxynonenal-mediated apoptosis: Critical role for heat shock protein 70 induction and stabilization of Bcl-XL J. Biol. Chem. 2007 282 33412 33420 Google Scholar Crossref Search ADS PubMed WorldCat Jacobs AT Marnett LJ HSF1-mediated BAG3 expression attenuates apoptosis in 4-hydroxynonenal-treated colon cancer cells via stabilization of anti-apoptotic Bcl-2 proteins J. Biol. Chem. 2009 284 9176 9183 Google Scholar Crossref Search ADS PubMed WorldCat Kakadiya R Wu YC Dong H Kuo HH Yih LH Chou TC Su TL Novel 2-substituted quinolin-4-yl-benzenesulfonate derivatives: Synthesis, antiproliferative activity, and inhibition of cellular tubulin polymerization ChemMedChem 2011 6 1119 1129 Google Scholar Crossref Search ADS PubMed WorldCat Kang MJ Jung SM Kim MJ Bae JH Kim HB Kim JY Park SJ Song HS Kim DW Kang CD et al. DNA-dependent protein kinase is involved in heat shock protein-mediated accumulation of hypoxia-inducible factor-1alpha in hypoxic preconditioned HepG2 cells FEBS J 2008 275 5969 5981 Google Scholar Crossref Search ADS PubMed WorldCat Kazemi Z Chang H Haserodt S McKen C Zachara NE O-linked beta-N-acetylglucosamine (O-GlcNAc) regulates stress-induced heat shock protein expression in a GSK-3beta-dependent manner J. Biol. Chem. 2010 285 39096 39107 Google Scholar Crossref Search ADS PubMed WorldCat Khalil S Luciano J Chen W Liu AY Dynamic regulation and involvement of the heat shock transcriptional response in arsenic carcinogenesis J. Cell. Physiol. 2006 207 562 569 Google Scholar Crossref Search ADS PubMed WorldCat Kim HR Kang HS Kim HD Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells IUBMB Life 1999 48 429 433 Google Scholar Crossref Search ADS PubMed WorldCat Kim SA Yoon JH Lee SH Ahn SG Polo-like kinase 1 phosphorylates heat shock transcription factor 1 and mediates its nuclear translocation during heat stress J. Biol. Chem. 2005 280 12653 12657 Google Scholar Crossref Search ADS PubMed WorldCat Laemmli UK Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 1970 227 680 685 Google Scholar Crossref Search ADS PubMed WorldCat Liu J Zhang D Mi X Xia Q Yu Y Zuo Z Guo W Zhao X Cao J Yang Q et al. p27 suppresses arsenite-induced Hsp27/Hsp70 expression through inhibiting JNK2/c-Jun- and HSF-1-dependent pathways J. Biol. Chem. 2010 285 26058 26065 Google Scholar Crossref Search ADS PubMed WorldCat Loewith R Jacinto E Wullschleger S Lorberg A Crespo JL Bonenfant D Oppliger W Jenoe P Hall MN Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control Mol. Cell 2002 10 457 468 Google Scholar Crossref Search ADS PubMed WorldCat Loots GG Ovcharenko I rVISTA 2.0: Evolutionary analysis of transcription factor binding sites Nucleic Acids Res. 2004 32 (Web Server issue), W217–W221 OpenURL Placeholder Text WorldCat Meng L Gabai VL Sherman MY Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis Oncogene 2010 29 5204 5213 Google Scholar Crossref Search ADS PubMed WorldCat Miller WH Jr Schipper HM Lee JS Singer J Waxman S Mechanisms of action of arsenic trioxide Cancer Res. 2002 62 3893 3903 Google Scholar PubMed OpenURL Placeholder Text WorldCat Min JN Huang L Zimonjic DB Moskophidis D Mivechi NF Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors Oncogene 2007 26 5086 5097 Google Scholar Crossref Search ADS PubMed WorldCat Mosser DD Theodorakis NG Morimoto RI Coordinate changes in heat shock element-binding activity and HSP70 gene transcription rates in human cells Mol. Cell. Biol. 1988 8 4736 4744 Google Scholar Crossref Search ADS PubMed WorldCat Murgo AJ Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies Oncologist 2001 6 Suppl. 2 22 28 Google Scholar Crossref Search ADS PubMed WorldCat Murshid A Chou SD Prince T Zhang Y Bharti A Calderwood SK Protein kinase A binds and activates heat shock factor 1 PLoS One 2010 5 e13830 Google Scholar Crossref Search ADS PubMed WorldCat Nueda A Hudson F Mivechi NF Dynan WS DNA-dependent protein kinase protects against heat-induced apoptosis J. Biol. Chem. 1999 274 14988 14996 Google Scholar Crossref Search ADS PubMed WorldCat Pelicano H Carew JS McQueen TJ Andreeff M Plunkett W Keating MJ Huang P Targeting Hsp90 by 17-AAG in leukemia cells: Mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C Leukemia 2006 20 610 619 Google Scholar Crossref Search ADS PubMed WorldCat Phillips PA Dudeja V McCarroll JA Borja-Cacho D Dawra RK Grizzle WE Vickers SM Saluja AK Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70 Cancer Res. 2007 67 9407 9416 Google Scholar Crossref Search ADS PubMed WorldCat Pirkkala L Nykanen P Sistonen L Roles of the heat shock transcription factors in regulation of the heat shock response and beyond FASEB J. 2001 15 1118 1131 Google Scholar Crossref Search ADS PubMed WorldCat Richter K Haslbeck M Buchner J The heat shock response: Life on the verge of death Mol. Cell 2010 40 253 266 Google Scholar Crossref Search ADS PubMed WorldCat Rossi A Ciafre S Balsamo M Pierimarchi P Santoro MG Targeting the heat shock factor 1 by RNA interference: A potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer Cancer Res. 2006 66 7678 7685 Google Scholar Crossref Search ADS PubMed WorldCat Sambrook J Fritsch EF Maniatis T Molecular Cloning: A Laboratory Manual 1989 Cold Spring Harbor, NY Cold Spring Harbor Laboratory Google Scholar Google Preview OpenURL Placeholder Text WorldCat COPAC Santagata S Hu R Lin NU Mendillo ML Collins LC Hankinson SE Schnitt SJ Whitesell L Tamimi RM Lindquist S et al. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer Proc. Natl. Acad. Sci. U.S.A. 2011 108 18378 18383 Google Scholar Crossref Search ADS PubMed WorldCat Shi Y Kroeger PE Morimoto RI The carboxyl-terminal transactivation domain of heat shock factor 1 is negatively regulated and stress responsive Mol. Cell. Biol. 1995 15 4309 4318 Google Scholar Crossref Search ADS PubMed WorldCat Soignet SL Maslak P Wang ZG Jhanwar S Calleja E Dardashti LJ Corso D DeBlasio A Gabrilove J Scheinberg DA et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide N. Engl. J. Med. 1998 339 1341 1348 Google Scholar Crossref Search ADS PubMed WorldCat Stanbridge EJ Flandermeyer RR Daniels DW Nelson-Rees WA Specific chromosome loss associated with the expression of tumorigenicity in human cell hybrids Somatic Cell Genet. 1981 7 699 712 Google Scholar Crossref Search ADS PubMed WorldCat Straif K Benbrahim-Tallaa L Baan R Grosse Y Secretan B El Ghissassi F Bouvard V Guha N Freeman C Galichet L et al. A review of human carcinogens—part C: Metals, arsenic, dusts, and fibres Lancet Oncol. 2009 10 453 454 Google Scholar Crossref Search ADS PubMed WorldCat Tabellini G Cappellini A Tazzari PL Fala F Billi AM Manzoli L Cocco L Martelli AM Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells J. Cell. Physiol. 2005 202 623 634 Google Scholar Crossref Search ADS PubMed WorldCat Taylor BF McNeely SC Miller HL States JC Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization Toxicol. Appl. Pharmacol. 2008 230 235 246 Google Scholar Crossref Search ADS PubMed WorldCat Tchenio T Havard M Martinez LA Dautry F Heat shock-independent induction of multidrug resistance by heat shock factor 1 Mol. Cell. Biol. 2006 26 580 591 Google Scholar Crossref Search ADS PubMed WorldCat Vlahos CJ Matter WF Hui KY Brown RF A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) J. Biol. Chem. 1994 269 5241 5248 Google Scholar PubMed OpenURL Placeholder Text WorldCat Vuky J Yu R Schwartz L Motzer RJ Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma Invest. New Drugs 2002 20 327 330 Google Scholar Crossref Search ADS PubMed WorldCat Wang JH Yao MZ Gu JF Sun LY Shen YF Liu XY Blocking HSF1 by dominant-negative mutant to sensitize tumor cells to hyperthermia Biochem. Biophys. Res. Commun. 2002 290 1454 1461 Google Scholar Crossref Search ADS PubMed WorldCat Wang X Grammatikakis N Siganou A Stevenson MA Calderwood SK Interactions between extracellular signal-regulated protein kinase 1, 14-3-3epsilon, and heat shock factor 1 during stress J. Biol. Chem. 2004a 279 49460 49469 Google Scholar Crossref Search ADS WorldCat Wang Y Theriault JR He H Gong J Calderwood SK Expression of a dominant negative heat shock factor-1 construct inhibits aneuploidy in prostate carcinoma cells J. Biol. Chem. 2004b 279 32651 32659 Google Scholar Crossref Search ADS WorldCat Westerheide SD Kawahara TL Orton K Morimoto RI Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death J. Biol. Chem. 2006 281 9616 9622 Google Scholar Crossref Search ADS PubMed WorldCat Wetzler M Earp JC Brady MT Keng MK Jusko WJ Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity—Pharmacodynamic drug-drug interaction modeling Clin. Cancer Res. 2007 13 2261 2270 Google Scholar Crossref Search ADS PubMed WorldCat Whitesell L Lindquist S Inhibiting the transcription factor HSF1 as an anticancer strategy Expert Opin. Ther. Targets 2009 13 469 478 Google Scholar Crossref Search ADS PubMed WorldCat Workman P Clarke PA Raynaud FI van Montfort RL Drugging the PI3 kinome: From chemical tools to drugs in the clinic Cancer Res. 2010 70 2146 2157 Google Scholar Crossref Search ADS PubMed WorldCat Wu YC Yen WY Lee TC Yih LH Heat shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic trioxide-induced mitotic apoptosis Toxicol. Appl. Pharmacol. 2009 236 231 238 Google Scholar Crossref Search ADS PubMed WorldCat Wu YC Yen WY Ho HY Su TL Yih LH Glyfoline induces mitotic catastrophe and apoptosis in cancer cells Int. J. Cancer 2010 126 1017 1028 Google Scholar PubMed OpenURL Placeholder Text WorldCat Yih LH Hsueh SW Luu WS Chiu TH Lee TC Arsenite induces prominent mitotic arrest via inhibition of G2 checkpoint activation in CGL-2 cells Carcinogenesis 2005 26 53 63 Google Scholar Crossref Search ADS PubMed WorldCat Zuo J Rungger D Voellmy R Multiple layers of regulation of human heat shock transcription factor 1 Mol. Cell. Biol. 1995 15 4319 4330 Google Scholar Crossref Search ADS PubMed WorldCat © The Author 2012. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please email: [email protected]

Journal

Toxicological Sciences – Oxford University Press

Published: Jul 1, 2012

Keywords: arsenic trioxide cytotoxicity heat shock factor 1 heat shock response apoptosis

There are no references for this article.